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Abstract
Modelling Early Initiation of HAART to Forestall
AIDS-related Lymphoma in South Africa: a
Cost-Effectiveness Analysis
I. Kyomugisha
Department of Mathematical Sciences
University of Stellenbosch,
Private Bag X1, Matieland 7602, South Africa.
Thesis: Msc (Math Sc)(Bio-math)
March 2017
The burden of cancer in low and middle income countries has been projected to shift
from 59% (in 2012) to 65% (by 2030) of all cancer cases globally. Since the intro-
duction of highly active antiretroviral therapy (HAART) in South Africa, there has
been a marked decline in AIDS-related illnesses and premature death. However, this
has not been the case with AIDS-related lymphoma which was observed to be on the
rise despite the large HAART roll-out programme. It was discovered that 37% of all
lymphoma cases diagnosed in 2009 in the Western Cape province, were HIV-related,
indicating a remarkable increase from 5% in 2002. The ineffectiveness of HAART in
reducing the incidence of lymphoma is largely attributed to late commencement of
treatment. However, increasing HAART coverage is still a major challenge to many
developing countries in Africa as well as South Africa due to limited resources.
Therefore, increasing early HAART initiation has a cost implication that needs to
be investigated in resource limited settings. In this study we used a deterministic
compartmental model to investigate the potential impact of initiating HAART at
ii
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different CD4 cell count levels on the incidence of lymphoma in HIV-infected individ-
uals. We also developed a linked transmission and health state transition (Markov)
model in TreeAge Pro to determine the cost-effectiveness of early HAART initiation
from the public healthcare payer perspective. The CD4 count driven transmission
model predicted lymphoma incidence in HIV-infected adults (aged 15 to 80 years)
over a period of ten years. The Markov model predicted the health outcomes and
costs. Data on transmission, transition probabilities, CD4 count thresholds, life ex-
pectancy, effectiveness and costs were obtained from literature. We compared early
initiation of HAART at a CD4 cell count of greater than 500 cells/µL to initiation
at less than 500 cells/µL, the current standard of care. Our primary outcomes were
Quality-adjusted life years (QALYs), expected costs, net monetary benefit and the
incremental cost-effectiveness ratio (ICER). Health outcomes and costs were dis-
counted at a rate of 5% per annum as recommended in Southern Africa. We also
performed deterministic sensitivity analyses to assess parameter uncertainty.
Results indicated that early HAART initiation prevents lymphoma cases and re-
lated deaths, translating to 3.76 QALYs gained over the 10-year time horizon (6.47
vs. 2.71 expected QALYs with HAART initiation at greater than 500 cells/µL and
less than 500 cells/µL, respectively). The incremental cost of early initiation was
$14,613 compared to the alternative. The net monetary benefit (NMB) of early
initiation was $90,581 and $30,063 for the alternative. HAART initiation at greater
than 500 cells/µL was therefore cost-effective with an ICER of $3,890/QALY gained.
Sensitivity analysis showed outcomes were sensitive to the effectiveness of HAART
in preventing lymphoma, with early initiation being more sensitive than the base
case. Therefore, early HAART initiation at CD4 greater than 500 cells/µL would
not only be effective in forestalling AIDS-related lymphoma but also cost-effective
in resource limited settings.
iii
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Uittreksel
Modelling Early Initiation of HAART to Forestall
AIDS-related Lymphoma in South Africa: a
Cost-Effectiveness Analysis
I. Kyomugisha
Department of Mathematical Sciences
University of Stellenbosch,
Private Bag X1, Matieland 7602, South Africa.
Tesis: Msc (Math Sc)(Bio-math)
Maart 2017
Die las van kanker in ’n lae en middel-inkomste lande is geprojekteer vanaf 59%
(in 2012) te skuif na 65% (in 2030) van alle kankergevalle wêreldwyd. Sedert die
bekendstelling van hoogs aktiewe antiretrovirale terapie in Suid-Afrika, daar was ’n
merkbare afname in vigs - verwante siektes en voortydige dood. Maar dit is nog nie
die geval met vigsverwante limfoom wat waargeneem om op te gewees die opkoms
ten spyte van die groot HAART uitrol program. Daar is vasgestel dat 37% van al
limfoom gevalle gediagnoseer in 2009 in Wes-Kaap was MIV-verwante wat dui op
’n merkwaardige toename van 5% in 2002. Die ondoeltreffendheid van HAART in
die vermindering van die voorkoms van limfoom is grootliks toegeskryf word aan die
laat aanvang behandeling. Maar, die verhoging van HAART dekking is nog steeds
’n groot uitdaging om baie ontwikkelende lande in Afrika, insluitend Suid-Afrika
as gevolg van beperkte hulpbronne. Daarom, die verhoging van die vroeë HAART
inisiasie het ’n koste-implikasie wat gevolg moet word ondersoek in hulpbron be-
perk instellings. Ons gebruik ’n deterministiese kompartementele model om die
iv
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potensiële impak van die inisiëring HAART op verskillende CD4-seltelling vlakke op
die voorkoms van limfoom in MIV-geïnfekteerde individue te ondersoek. Ons het
ook ’n gekoppelde transmissie en gesondheid toestand oorgang (Verborge) model in
TreeAge Pro om die koste-effektiwiteit van die vroeë HAART inleiding bepaal uit
die openbare gesondheidsorg betaler perspektief. Die CD4-telling gedryf transmissie
model voorspel limfoom voorkoms van MIV-geïnfekteerde volwassenes (15-80 jaar
oud) oor ’n tydperk van tien jaar. Die Markov model voorspel dat die gesondheid
uitkomste en koste. Data oor die oordrag , oorgang waarskynlikhede, tel CD4 drem-
pels, lewensverwagting, doeltreffendheid en koste is verkry uit die literatuur. Ons
vergelyk vroeë aanvang van HAART op ’n CD4-seltelling van meer as 500 selle/µL
na inisiasie teen minder as 500 selle/µL, die huidige standaard van sorg. Ons pri-
mêre uitkomste was lewe jaar Kwaliteit-aangepaste (QALYs), verwagte koste, netto
monetêre voordeel en die inkrementele koste-effektiwiteit verhouding (ICER). Ge-
sondheid uitkomste en koste word verdiskonteer teen ’n koers van 5% per jaar soos
aanbeveel in Suider-Afrika. Ons het ook uitgevoer deterministiese sensitiwiteitsa-
nalises om parameter onsekerheid te evalueer. Resultate het aangedui dat vroeë
HAART inisiasie verhoed limfoom gevalle en verwante sterftes, vertaal na 3.76 QA-
LYs wat oor die 10-jarige tydhorison (6,47 teen 2,71 verwag QALYs met HAART
inleiding op groter as 500 selle/µL en teen minder as 500 selle/µL , onderskeidelik).
Die inkrementele koste van vroeë aanvang was $14,613 in vergelyking met die alter-
natiewe . Die netto monetêre voordeel (NMB) van vroeë aanvang was $90,581 en
$30,063 vir die alternatiewe . HAART inleiding op groter as 500 selle/µL was dus
kostedoeltreffende met ’n ICER van $3,890/QALY opgedoen. Sensitiwiteitsanalise
het uitkomste was sensitief vir die doeltreffendheid van HAART in die voorkoming
van limfoom, met vroeë aanvang om meer sensitief as die basis geval. Daroom, vroeë
HAART inleiding op CD4 groter as 500 selle/µL sou nie net effektief in forestalling
vigsverwante limfoom, maar ook koste-effektief in beperkte hulpbronne instellings
wees.
v
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Chapter 1
Introduction
1.1 HIV and AIDS-related Cancers
Sub-Saharan Africa carries the greatest burden of HIV with about two-thirds of
HIV-infected people living in this region [82]. There has been a high HIV preva-
lence and increasing burden of HIV-associated malignancies in this resource-limited
region. HIV is known to attack cells that are critical to the human immune system
and destroys their ability to fight infections. The HIV virus targets the CD4+ T
lymphocytes, which are the most abundant white blood cells of the immune system.
Although HIV infects other immune cells, it mostly wreaks havoc on the CD4+ T
cells by causing their destruction and decline, thus decreasing the immune system’s
resistance to invaders. As a result, people who have developed AIDS are unable to
fight off infections by other viruses or bacteria and can die from infections that are
normally harmless because as the immune system weakens, the body is vulnerable
to life-threatening infections and cancers [19, 78]. These are normally referred to as
opportunistic infections.
In an HIV-infected individual, the viral load and CD4 cell count are determinants
of disease progression. The extent to which the immune system of an HIV-infected
individual is weakened, often depends on the viral load. The lower the viral load in an
individual, the stronger the immune system and thus, the less likely the development
of opportunistic infections and AIDS-associated malignancies. "However, it has been
shown that CD4 cell count is a better predictor of disease progression than viral
load" [81]. CD4 cell count levels are the best predictors of the risk of opportunistic
infections because the HIV virus usually targets these cells and destroys them. A
1
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healthy individual is said to normally have a CD4 cell count of (800 - 1200) cells/µL
[5]. Thus, a CD4 cell count below 500 cells/µL is usually an indicator of immune
suppression and vulnerability to opportunistic infections.
Several types of cancer that develop during states of immunodeficiency in HIV-
infected individuals are rare cancers associated with viral infection. Specific types
of cancer that have been found to appear mainly in people living with HIV are
Kaposi sarcoma, Non-Hodgkin lymphoma and Cervical cancer [19]. These cancers
are often called AIDS-defining conditions, meaning that if a person with HIV has
one of these cancers it can signify the development of AIDS.
According to the South African national HIV prevalence, incidence and behaviour
survey 2012 by the Human Sciences Research Council (HSRC), HIV prevalence
in South Africa has increased substantially. It was estimated that in 2012 about
6.4 million people were HIV positive (12.2% of the population) as compared to
5.2 million in 2008 (10.6% of the population), an increment of 1.2 million people
[73, 77]. With an increase in the number of people infected with HIV, there is most
likely to be an increase in incidences of opportunistic infections and AIDS-related
malignancies. Despite the various interventions (such as HAART initiation) put in
place to reduce the spread of HIV in South Africa, the current prevailing situation
is still of major concern as there is no noted decrease in the incidence of HIV. As
a result, the effectiveness and impact of the control measures in place has to be
re-evaluated and carefully analysed as there is a cost implication that could be a
financial burden to the country.
1.2 AIDS-related Lymphoma
Lymphoma is a cancer of the lymphatic system that starts in lymphocytes which
are a type of white blood cells made in the bone marrow, lymphatic tissue and also
in the blood. The lymphatic system is a network of lymphatic vessels that carry
lymph, a colorless fluid containing white blood cells, throughout the body. The
lymphatic system consists of lymph nodes which are found in clusters located in
the abdomen, groin, pelvis, underarms and neck. Other organs that are part of the
lymphatic system include the spleen, which makes lymphocytes and filters blood;
the thymus, an organ under the breastbone and the tonsils, located in the throat.
The major role of the lymphatic system is to defend the body against infections and
2
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disease [22, 57].
Lymphoma starts when normal cells in the lymphatic system change and grow
uncontrollably, forming a mass called a tumour. A tumour can be benign (non-
cancerous) or malignant (cancerous, meaning it can spread to other parts of the
body). Although lymphomas are often confined to lymph nodes and other lymphatic
tissue, they can spread to other types of tissue anywhere in the body (extranodal
disease). In contrast to lymphomas that occur in immunocompetent individuals,
AIDS-related lymphoma often occurs extranodally (such as in the primary central
nervous system lymphoma (PCNSL), gut or bone marrow) and has an aggressive
clinical course [16, 22].
There are mainly two types of lymphoma, namely; Hodgkin’s lymphoma (previously
known as Hodgkin’s disease) and Non-Hodgkin’s Lymphoma (NHL). The two lym-
phoma types are similar in appearance, with the same kind of symptoms and occur
in the same places but their difference is eminent under microscopic examinations.
Their difference is in the involvement of a specific type of lymphocyte known as the
Reed-Sternberg cells. Hodgkin’s lymphoma (HL) develops from abnormal B-cells
which are the Reed-Sternberg cells and Non-Hodgkin’s lymphoma does not involve
the Reed-Sternberg cells. HL tends to spread in a more orderly way than NHL.
Classification of lymphoma is complicated due to the multitude of subtypes. This
largely depends on genetic characteristics of affected cells, lymph nodes areas of the
body they originate in, and many other factors. Hodgkin’s lymphoma has five sub-
types and Non-Hodgkin’s lymphoma has about sixty classified subtypes according
to the World Health Organisation [22, 56, 57].
Non-Hodgkin’s lymphoma subtypes are classified mainly into B-cell lymphoma, T-
cell and natural killer (NK) cell lymphoma. The B-cell subtypes are the most
common, accounting for over 80% of all lymphomas. Examples of B-cell lymphomas
include; Diffuse large B-cell lymphoma, Primary effusion lymphoma, Burkitt’s lym-
phoma, Intravascular large B-cell lymphoma, Follicular lymphoma, Small cell lym-
phocytic lymphoma, Mantle cell lymphoma, Mediastinal (thymic) large B-cell lym-
phoma, etc [21, 56, 57]. T-cell and NK cell lymphoma subtypes include; Anaplastic
large cell lymphoma, Hepatosplenic lymphoma, Cutaneous T-cell lymphoma, An-
gioimmunoblastic T-cell lymphoma, NK-cell lymphoma and Peripheral T-cell lym-
phomas which are not specified [22, 51, 57]. NHL subtypes are known to be either
indolent (slow growing) or aggressive (fast growing). The aggressive lymphomas
3
Stellenbosch University  https://scholar.sun.ac.za
1.2. AIDS-related Lymphoma
are the most common with Diffuse large B-cell lymphoma being the most common
subtype and Follicular lymphoma being the most common indolent subtype. How-
ever, it is not unusual to find some patients with intermediate grade disease which
lies between indolent and aggressive. While in some cases indolent lymphoma may
transform to aggressive NHL [16, 22, 56].
HIV-infected individuals were found to be at increased risk of developing AIDS-
related lymphoma 60-200 times more than other individuals [1, 21]. Although
both hodgkin lymphoma and Non-Hodgkin lymphoma have been diagnosed in HIV-
infected people, the latter is more common. AIDS-related lymphoma can be di-
vided into three main types which are; Systemic NHL, Primary central nervous
system lymphoma and Primary effusion lymphoma (also known as "body cavity
lymphoma"). Incidence of NHL has been observed to be higher in men than women
in general.
The Tygerberg Lymphoma Study Group (TGLSG) in Western Cape, South Africa
was established in 2007 to investigate the impact of the HIV epidemic and Anti-
retroviral treatment policy on the incidence of HIV-related lymphomas (HRL) in
Western Cape, South Africa [1]. Their findings indicated that in contrast to devel-
oped countries, cases of HRL were on the rise in Western Cape, South Africa despite
the ART roll out plan that commenced in 2004.
Lymphomas specifically occurring in HIV patients are closely linked to other viral
diseases, thus, the HIV virus is not thought to be a direct cause of lymphoma,
but rather, it weakens the body’s defence system and increases susceptibility to
infections like Epstein-Barr and HHV-8 viruses which are associated with these
lymphoma types [43]. AIDS-related lymphoma is the second most common type
of AIDS-related cancer in Sub-Saharan Africa. HIV is said to increase the risk of
high grade lymphomas which are the aggressive types of lymphoma that are known
to grow quickly. Most AIDS-related NHLs belong to one of three categories of
high-grade B-cell lymphomas: Burkitt’s lymphoma, centroblastic lymphoma, and
immunoblastic lymphoma [23]. Burkitt’s lymphoma is the most common type of
high grade NHL in South Africa. Lymphoma is fatal if not treated early enough
and remains a significant cause of morbidity and mortality in people living with HIV
in Sub-Saharan Africa [3, 51].
4
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1.2.1 Lymphoma Diagnosis and Treatment
The symptoms of AIDS-related lymphoma depend on the location of the tumor.
Lymphoma can be asymptomatic or may present with symptoms such as fever,
sudden weight loss, night sweats, itchy skin and chills. However, the most common
early symptoms of lymphoma are painless swellings (swollen lymph nodes) in the
neck, groin, chest, underarm or abdomen. In cases where lymphoma starts from a
body organ, symptoms such as rashes, chest pain, cough, abdominal pain and lumps
under the skin, may be present [22, 56, 57].
The diagnosis of AIDS-related non-Hodgkin lymphoma often involves a complete
physical examination including the history of a patient’s habits and previous ill-
nesses. It also includes lymph node biopsy, which involves taking a sample of lymph
node tissue by needle or surgery to determine the presence of lymphoma [22, 56, 57].
The biopsy performed may include one of the following procedures:
• Removal of an entire lymph node (excisional biopsy).
• Removal of part of the lymph node (incisional biopsy).
• Removal of lymph node tissue by use of a wide needle (core biopsy).
• Removal of lymph node tissue by use of a thin needle (fine-needle aspiration
(FNA) biopsy).
• Removal of bone marrow, blood, and a small piece of bone through inserting a
hollow needle into the hipbone or breastbone (bone marrow aspiration biopsy).
Certain lab tests are also carried out to confirm presence of the disease and whether
it may have spread to other parts of the body. These tests often include; complete
blood count (CBC), spinal tap/lumbar puncture, HIV test and blood chemistry
analysis. A complete blood count test involves checking a blood sample for the
proportion of red blood cells, white blood cells and platelets. The spinal tap involves
extracting spinal fluid from the spine using a needle, then checking it for cancer
cells. In blood chemistry analysis, blood is screened for chemicals that are known
to indicate presence of the disease in certain organs.
Also Imaging tests are carried out to help identify the location and distribution
of enlarged lymph nodes, large tumors and other affected body organs. Imaging
5
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tests include X-rays, Computed tomography (CT) scan, Magnetic resonance imaging
(MRI) scan and Positron emission tomography (PET) scan [22, 56, 57].
If the above tests confirm the presence of lymphoma, then further additional tests are
carried out to determine the disease stage. Staging is important in order to identify
the lymphoma type and subtypes so as to determine the appropriate treatment to
use. Staging involves determining the extent to which the cancer has spread and
its location [22, 56]. Non-Hodgkin lymphoma has four stages of disease: stage I
(early disease) is when the cancer cells are in only one lymph node area of the body;
Stage II (locally advanced disease) is when the cancer cells are in two or more lymph
node areas above or below the diaphragm; Stage III (advanced disease) is when the
cancer cells are on both sides of the diaphragm; Stage IV (widespread disease) is a
situation where by lymphoma has spread extensively in the lymph nodes and other
body organs which are not part of the lymphatic system such as the liver, lungs,
cerebrospinal fluid and bone marrow [20, 27, 56]. AIDS-related lymphoma stages
may also be classified in terms of "E" and "S", where E represents extranodal disease
where by cancer is found in other areas of the body besides the lymph nodes or has
spread to areas surrounding the lymph nodes, and S represents the spleen, meaning
cancer cells are found in the spleen. Stage III disease can be further classified as
IIIE, IIIS and IIIE+S depending on the extent to which the lymphoma has spread.
If a patient is undergoing lymphoma treatment but the cancer keeps spreading out,
this condition is known as progressive disease, also called refractory NHL. Once
lymphoma has been treated and it reappears some time later on, it is said to be
recurrent or relapsed NHL [20, 22, 27].
Treatment of AIDS-related Lymphoma (ARL) mainly involves three standard ther-
apy types namely; chemotherapy, radion therapy and high dose chemotherapy with
stem cell/bone marrow transplant. In treating ARL patients, lymphoma therapy
is combined with AIDS treatment in most cases. ARL treatment also includes Im-
munotherapy, which is a type of biological therapy designed to boost the body’s
natural defense system to fight off cancer. However, in the early stages of disease,
the doctors may chose to watch and wait especially if the patient has indolent or low-
grade lymphoma without symptoms. During the watchful waiting period, patients
have to under go active surveillance where patients are monitored for possibility
of the cancer spreading [20, 56, 57]. Chemotherapy involves the use of anti-cancer
drugs to kill the cancer cells or hinder their ability to divide. The most common
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NHL treatment combination contains cyclophosphamide, doxorubicin, vincristine
and prednisone, known as CHOP. In some cases rituximab is added to CHOP.
Chemotherapy can always be used in combination with other treatments. Radi-
ation therapy involves the use of x-rays or other high-energy rays to destroy cancer
cells. Non-Hodgkin lymphoma is often treated with external beam radiation ther-
apy, administered alongside chemotherapy. Stem cell/bone marrow transplantation
involves replacing bone marrow the contains cancer with hematopoietic stem cells
which develop into healthy bone marrow. Hematopoietic stem cells are stem cells
that produce all other blood cells and are found in the blood stream and bone
marrow. Stem cell transplantation consists of two types, that is, Allogeneic and Au-
tologous, depending on the source of the stem cells used. Allogeneic involves the use
of stem cells from a donor and autologous involves using the patient’s own stem cells
that have been extracted and stored before chemotherapy . Stem cell transplant is
often used to treat patients with aggressive or recurrent lymphoma and is usually
administered in combination with high-dose chemotherapy [20, 22, 57].
Despite the improvement in prognosis and treatment of AIDS-related lymphoma,
there are some complications that have been observed as a result of late treatment.
Some HIV-positive individuals have been diagnosed with acute myeloid leukemia
which is associated with chemotherapy and also secondary malignancy a few years
after treatment which poses a challenge to the efficacy of the treatment used [12,
59]. However, there are continuous clinical trials being carried out currently to test
several other types of treatment for NHL and hopefully a more effective type of
therapy will be discovered soon.
1.3 HAART as Prevention of AIDS-related
Lymphoma
Over the years, since the introduction of HAART, there has been a noted decrease
in Kaposi Sarcoma incidence and other AIDS defining illnesses but this has not been
the case with non-Hodgkin lymphoma which has been increasing [79]. South Africa
has the largest Antiretroviral Therapy (ART) roll-out programme in the world. The
current standard practice in South Africa is to commence antiretroviral therapy at
CD4 cell count of less than 500 cells/µL but prior to 2014, the standard practice
was to initiate treatment at CD4 less than 350 cells/µL which was implemented in
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2011 and at CD4 less than 200 cells/µL before then. It was estimated that by mid
2012, over two million HIV-infected people in South Africa were on antiretroviral
therapy, with the number of females in the programme surpassing the number of
male patients. On average, it was estimated that 31.2% of the total number of
HIV-positive people in South Africa were enrolled on ART in 2012 [73, 77].
The causes of most lymphomas are still unknown to clinicians and researchers, which
makes prevention of the disease rather difficult. However, in order to address this
kind of situation, one can take into consideration the risk factors related to devel-
oping lymphoma, such as immune deficiency. In the world today, HIV infection is
one of the leading causes of immunodeficiency. Therefore, HIV prevention through
antiretroviral therapy can be used as a strategy for improving the immunity of HIV-
infected individuals, thus reducing the risk of immunodeficiency and AIDS-related
malignancies such as non-Hodgkin lymphoma.
Currently, the standard antiretroviral therapy in use is Highly Active Antiretroviral
Therapy (HAART) which consists of a combination of three drugs that suppress
HIV replication, thus reducing immunosuppression. HAART, therefore improves
the life expectancy of people living with HIV by reducing their chances of morbidity
and mortality. In South Africa, HAART was introduced in 2004 and by 2008 it had
an estimated coverage of approximately 371,731 patients [2, 28].
HAART has been highly effective in reducing the levels of human immunodeficiency
virus, thus boosting immunity and increasing the chances of survival of HIV-infected
people [24]. Improved immunity has led to a decline in incidences of life threatening
illnesses such as AIDS-related malignancies in people living with HIV.
Since the introduction of HAART, there has been a decline in the incidence of non-
Hodgkin lymphoma among HIV-infected individuals. However, in order to reduce
the risk of developing non-Hodgkin lymphoma, early initiation of highly active anti-
retroviral therapy is advocated for. Studies have been carried out to show that low
CD4 cell count increases the risk of several cancers after starting HIV therapy [89].
A study by Guiguet et al. [47] reported that the most predictive risk factor for all
cancers, except anal cancer, is a patient’s CD4 cell count and patients with a CD4
cell count of less than 200 cells/µL are most at risk of death. According to Biggar
et al. [15], genetic errors of increased lymphocyte turnover could also increase the
risk of developing non-Hodgkin lymphoma.
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1.4 Health Interventions
A health intervention is a combination of strategies, policies or programs designed
to improve the health status of individuals or an entire population, through shifting
the whole distribution of health risk by addressing underlying social, economic and
environmental conditions [49, 63]. A health intervention can also be seen as a
deliberate activity aimed at improving the health of individuals by reducing risk,
duration or severity of a health problem. Health interventions can be in the form of
treatment to be administered, screening tests or even primary prevention techniques
such as vaccination.
The importance of health interventions is to reduce disease incidences or compli-
cations that could cause accelerated morbidity and mortality in the population af-
fected, hence improving quality of life and the life expectancy of individuals. The
benefits of these interventions are known as health outcomes which can be in form
of the number of deaths averted or improved years of life.
The effectiveness of a health intervention is determined by the improvements in
health states and the resulting effects on life expectancy of individuals. In order
to make a decision on the best choice of intervention, the efficiency of all available
interventions is put into account. However, in order to maximise health benefits
within a given budget, we need to know the cost per year of life saved and/or the
cost per year of quality-life gained with that intervention. Therefore, for optimal
use of resources available, we aim at minimizing the number of new infections in the
population and thus maximizing the number of years lived in good health. It is thus
imperative to carry out cost-effectiveness analysis of interventions put in place to
prevent diseases in resource limited settings, in order to identify the strategies that
offer the highest value for resources used.
1.4.1 QALYs and DALYs
Disability Adjusted Life Years (DALYs) and Quality Adjusted Life Years (QALYs)
are standardized measures of the effects of a disease on the length of life and also
take into consideration the negative effects of morbidity. Health programmes are
geared towards averting DALYs and gaining QALYs.
QALYs can be seen as a measure of quality and quantity of life, that is a year of
life lived in perfect health. QALYs are patient preferences of health states, where
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by a year of life in one particular health state is more desirable than the other,
for example, a year of life without lymphoma is more desirable than a year with
lymphoma. The average number of QALYs we can expect to live at any given age
is known as the Quality Adjusted Life Expectancy (QALE) which can be defined as
the expected average number of years lived in perfect health. Health interventions
aim to increase the QALYs of individuals in a given population thus offering the
benefits of moving from a less desirable health state to a better one for a given
period of time.
The DALYs are an indicator of how much people are disabled by their illness. The
DALY is a quantitative measure of disease burden, that is, the number of years
lost due to a certain disease or years of life lived in a certain disease state. DALYs
can be used for direct comparison of disease burden and thus permit comparison
of treated and untreated diseases. They also aid in comparison of different disease
interventions such as treatment expansion versus prevention campaigns. DALYs
comprise of mortality and morbidity. Mortality is a measure of life lost due to
premature death and morbidity is a measure of all non-fatal chronic incidences such
as illness episodes. The DALYs calculation is given by the overall sum of the number
of years of life lost due to a disease and the number of years lived with a disability
caused by the disease. Therefore;
DALYS = Mortality + Morbidity,
where mortality and morbidity are given by
Mortality = Life expectancy - Age at death
Morbidity = Disability weight × Duration of disability
The disability weight is a severity rating ranging from 0 to 1 given to each illness ef-
fect, with 1 implying fully disabled/dead and 0 standing for fully healthy/no disabil-
ity. According to the global burden of disease 2013 study [68],the disability weights
for symptomatic HIV, HIV/AIDS on ART and AIDS without ART are 0.274, 0.078
and 0.582 on average respectively. While for cancer with primary treatment the
average disability weight is 0.288, metastatic cancer, 0.451 and when the cancer is
in terminal phase, the disability weights on average are 0.54 with medication and
0.569 without medication.
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1.5 Cost-Effectiveness Analysis
Cost-Effectiveness Analysis (CEA) in public health is used to asses health care in-
terventions in terms of the benefits they provide. Reporting of results is usually in
terms of resources needed to produce an extra unit of change in health effectiveness.
CEA compares two or more health interventions in terms of their costs and effective-
ness. The incremental cost-effectiveness ratio (ICER) is often used to express the
results (a lower cost effectiveness ratio implies a higher degree of comparative value
and vice versa). The main purpose of CEA therefore, is to examine efficiency of
activities so as to ensure the best use of available resources and identify possibilities
of reducing costs or extending benefits for the same costs.
In health evaluation, an intervention is regarded as cost-effective if;
• It is less costly but as effective as the competing alternative. The competing
alternative is the intervention being compared with the intervention of interest.
• It is more effective and more costly but the added benefit is worth the addi-
tional cost.
• It is less effective and less costly, where the added benefits are not worth the
additional costs.
• It is cost saving with an equal or better outcome.
Interventions that include multiple strategies are usually the most effective in giving
rise to desired change.
According to the World Health Organisation, a health intervention is considered to
be cost-effective if it costs less than three times the national annual gross domestic
product (GDP) per capita, per disability adjusted life year (DALY) averted. Further,
if an intervention costs less than once the national annual GDP per capita, it is
considered highly cost-effective. The GDP of a country is a measure of the size of
its economy. It represents the monetary value of all goods and services produced
within a country’s geographic borders over a specified period of time.
Cost-effectiveness analysis is used in forecasting the effects of one intervention strat-
egy in comparison to another in terms of years of life lost, or years of life gained
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and the related costs, as a result of the intervention and health care costs in order
to estimate cost-effectiveness.
In order to determine the cost-effectiveness of the interventions under consideration,
we review program financial and services records over a given period of time to
quantify the resources used, associated costs and clients served.
1.6 Problem Statement
People living with HIV have been found to be at an increased risk of developing
AIDS-related lymphoma 60-200 times more than other people. The human immun-
odeficiency virus (HIV) which causes AIDS is still a major public health challenge
in the world today, mainly due to the rising incidences of cancers associated with
HIV infection, despite the various prevention strategies put in place to prevent HIV
progression. There is still an urgent need to curb HIV spread and prevent incidences
of AIDS-related malignancies in Sub-Saharan Africa, although resources available
for interventions are limited. This creates an increasing need to identify the best
intervention option that gives the best value for available resources. Thus, the need
for Cost-Effectiveness Analysis of prevention strategies in place and those under
consideration.
1.7 Research Question
With the increase in lymphoma incidence, and given the challenges that surround
treatment of lymphoma in HIV-infected individuals, there is need to examine the
economic impact there of. It is therefore imperative to determine how the timing of
HAART initiation could impact the incidence of AIDS-related lymphoma and the
associated cost-effectiveness. Therefore the question is:
Would increased early initiation of highly active antiretroviral therapy (HAART) be ef-
fective and cost-effective in forestalling AIDS-related lymphoma in South Africa?
1.8 Aims/Goals
The goals of this study are as follows:
12
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i. To show the impact of early initiation of HAART on the incidence of AIDS-
related non-Hodgkin lymphoma and the associated cost-effectiveness.
ii. To guide the decision-making process of policy-makers regarding prevention and
treatment of AIDS-related lymphoma in resource limited settings.
1.9 Objectives
The study objectives are as follows:
i. To examine the impact of early HAART initiation on Lymphoma incidence in
people living with HIV.
ii. To asses the effectiveness of HAART in forestalling AIDS-related lymphoma.
iii. To examine the impact of antiretroviral therapy on the quality of life of HIV-
infected individuals in South Africa.
iv. To determine the net costs and effectiveness of early therapy initiation in South
Africa.
1.10 Significance of the Study
With the advent of highly active antiretroviral therapy (HAART), HIV-1 infection
is now manageable as a chronic disease in patients who have access to medication
and who achieve durable virologic suppression (Palella et al. 1998 [66]). However,
reports have shown that complete immune reconstitution may not be possible if
the commencement of HAART is at a stage when the CD4 cell count of an infected
person is very low [18, 89]. In our study therefore, we aim at showing the advantages
of early therapy initiation to the immune system of HIV-infected individuals.
Although quite a number of studies have been carried out to determine the efficacy
of HAART in reducing HIV infection, such as Granich et al. 2012, Auvert et al.
2004, Sterling et al. 2001, Opravil et al. 2002 [9, 46, 65, 81], limited attention has
been given to early HAART initiation as prevention for AIDS-related malignancies.
We thus assess the potential impact of early HAART initiation on the incidence
AIDS-related lymphoma.
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A search carried out by MEDLINE for articles published in 2007 relating to cost-
effectiveness, cost utility or economic evaluation revealed that quite a small propor-
tion of such publications were from developing countries despite limited health care
resources. The search revealed that only 7% of the 564 articles were from develop-
ing countries and only eight were from Africa [74]. This is an indication of the gap
in this area of research in Africa and therefore need for more studies in economic
evaluation to inform health policy.
1.11 Key Terminology
HIV, HAART, CD4 cell count, Non-Hodgkin Lymphoma (NHL), AIDS-related lym-
phoma (ARL), Cancer, Malignancies, Cost, Cost-effectiveness Analysis (CEA), In-
cremental cost-effectiveness ratio (ICER), Disability-adjusted life year (DALY), Quality-
adjusted life year (QALY).
1.12 Brief Chapter Overview
In chapter one we have looked at the background of HIV and AIDS-related Lym-
phoma and the motivation for our research. Going forth, in the next chapter we will
review some of the previous studies that are related to our research problem in order
to justify our approach and method used to address the research problem in ques-
tion. In chapter three, we shall elaborate on the methods used for our research work,
analysing the mathematical model formulated and decision tree created. In the final
chapter, we then present and explain the results and give some recommendations
for future research.
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In this chapter we review some of the studies related to HIV/AIDS prevention, the
impact of HAART on HIV incidence and AIDS-associated malignancies in published
literature. We also review some of the existing interventions for AIDS-related cancers
and their cost-effectiveness.
2.1 Impact of HAART on HIV in Sub-Saharan
Africa
A study by Auvert et al. 2004 [9] to determine the impact of HAART on HIV
transmission and spread in South Africa revealed that HAART could reduce the
annual risk of HIV transmission by approximately 11.9%. The cohort study was done
on a random sample of about one thousand men and women between the ages of 15
- 49 years in a high HIV-1 prevalence township in Johannesburg. According to their
findings, prevalence of HIV-1 was 21.8%, and 9.5% of these were eligible for HAART,
while 6.3% would need to start treatment in each of the next three years. Only a
small proportion of partnerships involved a spouse with a CD4 cell count below
200 cells/µL and would have benefited from HAART reducing transmission (by
decreasing the plasma HIV-1 RNA load [81]). There was a significant improvement
in the health status and life expectancy of HIV-infected patients enrolled on ART
observed among the cohort. However, it was estimated that if the threshold for
HAART intiation had been adjusted to less than 350 cells/µL at the time of the
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study, the impact of HAART on the short term spread of HIV would have been
greater. It was estimated that had the threshold of ART initiation been raised to
less than 350 cells/µL at that time, 56.3% of HIV patients would be eligible to start
ART and as a result the reduction in transmission of HIV of 50% for spousal and
59.3% for non-spousal relationships would benefit from the intervention. Also the
annual risk of HIV transmission would be reduced by 71.8%. This study indicates the
importance of HAART in reducing HIV infection and thus narrowing the possibility
of increased incidence of AIDS-related malignancies. The less the number of people
infected with HIV, the less the number of HIV-related cancers that will be expected.
A study by M. Badri et al. 2006 [11] to determine when to initiate highly active
antiretroviral therapy in sub-Saharan Africa showed that there was an increase in
clinical benefits of early HAART initiation in South Africa. The model used in
this study had 7 health states defined by three CD4 cell count thresholds,that is,
less than 200 cells/µL, (200 − 350) cells/µL and greater than 350 cells/µL classi-
fied by two treatment alternatives of ART and No-ART. The study used a cohort
of 10,000 patients which was run over 50 years so that almost all of the patients
were dead when it terminated. Cost-effectiveness analysis was carried out using a
markov state-transition model with Monte Carlo simulation in TreeAge Pro. It was
observed that 295 patients died from the No-ART group which was very signifi-
cant as compared to only 34 that died from the HAART group. The death rate of
patients in the class of CD4 count less than 200 cells/µL was significantly greater
than that of patients in the other two classes. Also the study related the decline
in the incidence of AIDS, Tuberculosis and death to early initiation of treatment.
The life expectancy of patients on HAART was found to be in the range of 18.8 to
23.3 years. Therapy initiation at a CD4 cell count of greater than 350 cells/µL was
shown to be more cost-effective with an incremental cost-effectiveness ratio (ICER)
compared to initiation at (200−350) cells/µL, of US$1,137 per quality-adjusted life
year (QALY), while initiation at (200 − 350) cells/µL had an ICER of US$616 as
compared to initiation at less than 200 cells/µL [11]. The study showed that for
people living with HIV, HAART is reasonably cost-effective and most effective if
initiated at a CD4 cell count level of greater than 350 cells/µL . This result indi-
cates that initiating antiretroviral therapy at an early stage is beneficial in terms
of costs and additional clinical benefits. However, given that the study period was
only 22 months, this period is not sufficient enough to rely on the results indicating
that CD4 cell count is a better predictor of HIV progression than HIV-RNA levels
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in patients receiving HAART.
Leigh F. Johnson et al. 2011 [54] designed a model to determine the impact of
antiretroviral treatment initiation policy on the rate of ART uptake using data from
Masiphumelele settlement community in Cape Town. The study was driven by
the uncertainty of the impact of the new ART initiation policy at the time on the
number of patients that would get enrolled on ART. Future ART uptake projections
were also limited by the uncertainty surrounding the rate at which patients who
had previously stopped taking treatment restart ART. The data from Masiphumele
community also helped to address the challenges encountered by several other similar
studies as a result of loss to follow up. The rate of ART initiation was estimated
using the number of patients starting ART in the community, stratified by gender,
year of initiation, CD4 cell count and previous enrolment on ART. Results from the
study indicated that despite the expansion of eligibility criteria for starting ART
to include patients with CD4 cell count in the range (200− 349) cells/µL, the rate
of ART initiation of patients within that category was considerably low especially
among male HIV-infected individuals. Asymptomatic patients with CD4 cell count
between 200 cells/µL and 350 cells/µL were less likely to know their status and
thus less likely to start ART which explained the small increment in the number
of patients enrolling on ART despite the increased eligibility threshold. The rate
at which patients with CD4 cell count greater than 200 cells/µL enrolled on ART
was largely dependent on the number of patients in that category that went for
HIV testing and were thus aware of their status. The rate of ART initiation among
treatment-naive patients with low CD4 cell count of less than 200 cells/µL was
found to be higher than that of patients that had previously dropped out of the
ART programme. From this study we see that despite the change in ART initiation
threshold, the actual change in the number of patients enrolling on ART was not
very significant. This implies that in order to increase ART initiation, several other
strategies such as increasing awareness and HIV testing should be taken into account
besides raising the eligibility threshold.
A study by Sterling et al. 2001 [81] to determine the clinical response to HAART
of HIV-infected individuals was done by assessing disease progression according to
the levels of HIV-1 RNA and CD4 cells in both the patients on treatment and those
not receiving HAART. This study was done with a cohort from the John Hopkins
hospital HIV clinic. The cohort comprised of 1014 HIV patients of whom 530 were on
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HAART and the cohort was followed up for 22 months on average. It was observed
that among the patients who had started HAART with CD4 cell count less than 200
cells/µL, there was a reduced risk of disease progression due to treatment in contrast
to those who did not receive treatment. However, patients with CD4 cell count
greater than 200 cells/µL prior to HAART initiation did not show any statistically
significant effects of HAART on HIV disease progression. Patients on HAART with
CD4 cell count less than 200 cells/µL were found to have the highest risk of disease
progression regardless of their level of HIV-1 RNA. The study indicated that CD4
cell count was a better predictor of which patients would benefit more from HAART
than their level of HIV-1 RNA.
2.2 Cost-Effectiveness Analysis of HAART and
HIV Interventions in Africa
There have been several studies to determine the cost-effectiveness of HAART in
resourse limited settings. In this section, we look at the research findings of some of
these studies.
A review study by Creese et al. 2002 [30] to determine the cost-effectiveness of
HIV/AIDS interventions in Africa indicated a big margin in the cost-effectiveness
of different interventions. The study was carried out using expert consultations and
databases with more than sixty reports identified that measured the cost (in US$)
and effectiveness of HIV/AIDS interventions in Africa. Only 24 of these reports sat-
isfied the criteria for inclusion and were used to determine the cost per HIV infection
averted and QALY gained for 31 interventions in the year 2000. The results of this
study revealed that HIV could be prevented with interventions like blood safety
measures, condom distribution and treatment of sexually transmitted diseases at a
cost of $11 and a QALY gained at $1. Interventions such as voluntary counselling
and testing, mother-to-child prophylaxis and treatment of Tuberculosis had a cost
less than $75 per QALY gained. Other interventions involving antiretroviral ther-
apy and home-based care programmes were found to be much more expensive with
home-based care costs ranging from $100 to $1000. This study highlights the im-
portance of carrying out cost-effectiveness analysis in Africa for better management
of available resources. However, this research report was rather confusing as they
seemed to refer to DALYs as desired and yet in reality it is the QALYs that are
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desired and thus gained while the years of life lost due to disability (DALYs) are
undesired and therefore minimised.
A cost-effectiveness analysis of expanding ART for prevention and treatment of HIV
in South Africa was carried out by Granich et al. 2012 [46]. The study considered
four CD4 cell count thresholds for eligibility of initiating antiretroviral therapy and
a 90% coverage of HIV testing among the age group of 15 to 49 years with an as-
sumption of ART reducing HIV transmission by 92%. Findings from this study
indicated that increasing ART initiation at CD4 less than 350 cells/µL could po-
tentially reduce new HIV infection by 265,000 and 1.4 million over 5 and 40 years
respectively. Also the same strategy could reduce deaths by 200,000 and costs by
$504 million in 5 years and approximately 15.7 million DALYs averted and 3.9 billion
dollars saved over 40 years. Initiation at CD4 cell count less than 500 cells/µL was
also found to potentially reduce mortality by 1.9 million and DALYs by 14.8 million
in 40 years with cost reductions of about $100 million in 5 years and $5 billion in
40 years. While considering initiation at all CD4 cell count levels would further
reduce infections by 3.3 million, deaths by 3.5 million and DALYs by 25.7 million
with a cost saving of $10 billion in 40 years compared with initiation at CD4 count
less than 350 cells/µL. Further more, it was also found that if ART could reduce
transmission by 99%, savings could reach $17.5 billion with initiation at all CD4 cell
count levels. This study showed the importance of ART initiation at a higher CD4
cell count threshold in controlling HIV spread and bringing about improved quality
of life, reduced costs and more lives saved. We can therefore see that increased early
ART initiation for HIV prevention and treatment in South Africa is cost-effective
over time.
A study by Badri et al. 2005 [10] to asses the cost-effectiveness of HAART in
South Africa indicated that use of HAART was cost-effective. The study compared
the costs and utilisation of HIV-1 related services among patients on HAART and
those not receiving antiretroviral therapy (but were accessing other HIV-related care
services) in the Cape Town AIDS cohort. The cohort comprised of 1,630 patients
of which 292 received HAART and the rest had not access to antiretroviral therapy
throughout the study. Of those who received ART, 27 had AIDS and 235 of the
no-ART patients also had AIDS. HAART initiation was stratified by CD4 cell count,
WHO stage of AIDS, age and social-economic status. About a third of the patients
in the matched non-AIDS group (with HAART and no-ART) had a CD4 cell count
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of less than 200 cells/µL. Progression of disease was observed to be significantly
lower among HAART patients with a median of 4.1 years than in the no-ART with
median 3years in the non-AIDS cohort. On the other hand, in the AIDS group, 77%
of the patients had CD4 count less than 200 cells/µL, median progression time was
3.1 years and 1.4 years among the HAART and no-ART groups respectively. The
incremental cost per year of life gained for AIDS patients was cost saving for the two
HAART price scenarios (US$730 per annum - scenario 1 and US$181 per annum -
scenario 2) considered. The study results indicated that for the no-AIDS patients
the mean number of in-patient days for individuals on HAART were significantly
less than those in the no-ART group and the average service provision for the no-
ART group was relatively higher than the HAART group under price scenario 2
but was considerably lower under price scenario 1. The incremental cost per year
of life gained under HAART price scenario 1 was $1,622 and $675 for scenario 2.
For patients with AIDS, the mean in-patient days for no-ART group were much
higher than that of the HAART group but the mean out-patient visits were not
very different for both groups. The average service provision was however found
to be much higher among the no-ART group than in the HAART group regardless
of the price scenario. The incremental cost per year of life gained here was cost-
saving in both scenarios of HAART prices. From this study we can deduce that
HAART is cost-effective in South Africa and is even more cost saving if the price of
HAART is reduced to about $181 per annum. Therefore with the use of HAART as
an intervention for prevention of HIV progression, there will be savings on hospital
utilisation and end of life care for HIV-infected patients thus resulting in reduction
of general health care costs. However, we note that from 1995 to December 2000
(the period in which this study was done), HAART was not yet available in the
healthcare sector of South Africa that is publicly funded.
2.3 AIDS-related Lymphoma Progression and
Interventions
There has not been much done on mathematical modelling of AIDS-related lym-
phoma in Africa. With regards to published studies, there is none on mathematical
modelling of lymphoma yet.
However, in a study done by M.D Akinlotan and F. Nyabadza at Stellenbosch Uni-
versity, 2013 a mathematical model of CD4 cell count driven AIDS-related non-
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Hodgkin lymphoma was developed and analysed [6]. According to their findings,
patients with a CD4 cell count less than 200 cells/µL have a higher chance of devel-
oping AIDS and lymphoma therefore, as the incidence of lymphoma increased among
this group. They also predicted that the increased effective use of HAART in the
population, could significantly reduce the incidence of lymphoma in HIV-infected
patients.
Existing reports on AIDS-related lymphoma interventions are mainly in the form
of comparing treatment options e.g Best et al. 2005, De witt et al. 2013, Marti-
Carvajal et al. 2009 [14, 35, 60]. Only a few studies have been done regarding
lymphoma prevention in HIV patients and these are in relation to the timing of
antiretroviral therapy initiation.
A study by Stebbing et al. 2004 [79] to determine the influence of HAART and im-
munologic factors on the risk of non-Hodgkin lymphoma revealed that the effective
use of HAART could prevent NHL through maintaining CD4 and CD8 counts. The
study investigated changes in innate and adaptive immune functions and confirmed
that HAART leads to delays in cancer progression. It was observed that the pro-
tease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) in
HAART are equally effective in protecting against cancer. Also, it was noted that
a decrease in immune parameters predisposes individuals to AIDS-related cancers.
Of the 9,621 HIV-infected patients in the cohort study, 280 patients had developed
lymphoma and of these, 206 had systemic non-Hodgkin lymphoma, 55 had primary
celebral lymphoma and 19 had hodgkin’s disease. It was observed that lower T-cell
and natural killer cells significantly predisposed individuals to systemic NHL. The
study also revealed that a low CD4 cell count, together with a CD8 count of greater
than 846 cells/µL was sufficient enough to offer protection from NHL.
Crum-Cianflone et al. 2009 [31] carried out a cohort study to describe the trends in
the incidence of cancers among HIV-infected people and the impact of antiretroviral
therapy. This study was done on over 4 thousand HIV-infected U.S military bene-
ficiaries with 33,486 person-years of follow-up for twenty years. The study revealed
that 10 percent of the cohort developed cancer and the rate of AIDS-related cancers
increased between the early (1984-1990) and late (1991-1995) pre-HAART eras and
reduced significantly during the HAART era. It was also observed that low CD4 cell
count, lack of HAART and AIDS diagnosis were predictors of AIDS-related cancers.
The study indicated that HAART significantly reduces chances of developing AIDS
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defining cancers and non-AIDS defining cancers in HIV-infected individuals. This
study therefore highlights the importance of HAART in reducing the incidence of
AIDS-related cancers.
Besson et al. 2001 [13] carried out a study using HIV-infected patients in the French
Hospital Database on HIV to investigate the changes in AIDS-related lymphoma
before and after the introduction of HAART. Their findings indicated a decrease in
the incidence of AIDS-related lymphoma from 86 per 10000 person-years during the
first period of 1993-1994 to 42.9 per 10000 person-years during the second period
of 1997-1998. It was observed that patients with similar CD4 cell counts in the
first and second period were at equal risk of developing AIDS-related lymphoma.
Patients with CD4 count greater than 350 cells/µL were found to be at lower risk of
developing lymphoma and those with a CD4 cell count less than 50 cells/µL had the
highest risk of developing AIDS-related lymphoma. It was also observed that the
number of patients at risk of developing lymphoma with a CD4 cell count less than
200 cells/µL decreased fron 49.5% to 24.5% between the two periods and during
the second period 64% of the patients diagnosed with ARL had been on HAART.
There was significant increase in survival of patients from about 6.3 months in the
first period to about 21.2 months in the second period. This increase in survival was
attributed to the change in proportion of patients on HAART from 40% to 100%
between the two periods. The results of this study are indicative of the importance
of HAART in reducing the risk of lymphoma among patients with low CD4. From
this study we can also deduce that early therapy initiation is important in reducing
the incidence of lymphoma in HIV-infected people.
A study by Achenbach et al.2011 [3] to evaluate the survival of patients after diag-
nosis of cancer revealed that there are several factors that contribute to mortality
in HIV-infected individuals diagnosed with cancer. These factors include failure of
ART to completely suppress HIV, the cancer stage at diagnosis and inaccessibility
of cancer treatment. The study was carried out on a cohort of HIV-positive patients
enrolled on ART for atleast six months before being diagnosed with cancer. The
results of the study showed that on average, patients developed cancer after three
years and only 92% of them were still on ART at the time of cancer diagnosis. Over-
all, more than 3% of the patients on ART developed cancer and the mortality rate of
these patients was found to be 20.6 per 100 person-years and their overall two-year
survival rate was at 58%. There was increased mortality among patients with low
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CD4 cell count and most of the patients had low nadir CD4 count. This finding fur-
ther stresses the point that early ART initiation is vital for immune reconstitution
and prevention of HIV-associated malignancies.
A case-control study by Stein et al. 2008 [80] looked at the risk of HIV-1 associ-
ated cancers among the South African black population. The study confirmed the
strong link between Kaposi sarcoma, non-Hodgkin lymphoma and HIV infection.
An increased risk of developing NHL among the black HIV-infected patients that
is consistent with other research studies done with different population groups in
Africa was observed. There was an association between Hodgkin lymphoma and HIV
observed as well as several other virus associated cancers. The risk of HIV-infected
individuals developing cancer was higher than HIV-negative individuals, with the
risk of Kaposi sarcoma about 50 times high, non-Hodgkin lymphoma 6 times high,
and other cancers such as cervical cancer, squamous cell skin cancer, anogenital and
Hodgkin lymphoma (1.5− 2.5) times high. Highly active antiretroviral therapy was
not routinely available during the study period and thus the effects of treatment
on cancer incidence could not be readily established. This study shows that the
risk of HIV-related cancers among HIV-infected individuals in South Africa is the
same as in other African countries and is slightly lower than that observed in devel-
oped countries. The significance of this study is to see the spectrum of HIV-related
cancers in the South African HIV-positive population prior to initiation of HAART.
A review study, taking into account the epidemiology, diagnosis and treatment of
AIDS-related non-Hodgkin Lymphoma in high prevalence resource poor setting was
carried out by Ulrickson et al. 2012 [82]. The study examined several published
literature on AIDS-related NHL comparing the findings of different studies from
Africa and other developed nations in the pre-combination antiretroviral therapy
(pre-cART) and post-cART eras. However, the true incidence of NHL in Africa
was believed to be higher than that documented but limited by inefficiency in data
collection and inaccessibility of medical care. It was found that in Africa on average,
patients developed HIV-related complications at a higher CD4 count than those in
developed countries. This study highlights the fact that access to cancer care is a
major challenge in resource poor settings due to the high costs involved thus leading
to difficulties in increasing accessibility to treatment for patients who are in need.
Despite this, it was estimated that the cost of inaction was more significant to the
situation in developing countries than the actual cost of accessing treatment and
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care. Improvement in treatment of HIV-related lymphoma in developing countries
was largely attributed to accessibility to antiretroviral therapy, early detection of
the disease and effective management of other opportunistic infections. This study
brings to attention the fact that cancer care and treatment is very costly and there-
fore much emphasis needs to be put on prevention and early detection rather than
treatment of advanced disease. End stage cancer is much more expensive to take
care of due to the intensive therapies required and the high risk of non-response to
therapy.
2.4 Conclusion
In conclusion from the above studies, we can deduce that HAART is very instru-
mental in reducing the risk of HIV-related malignancies among people living with
HIV in Sub-Saharan Africa. Where as it is important to increase HAART coverage
for prevention of AIDS-related cancers, the timing of HAART initiation is crucial
to this cause. We also observe that concurrent treatment of HIV and HIV-related
opportunistic infections plus early diagnosis and treatment of these cancers will
lead to increased overall survival among HIV-positive individuals. With these ob-
servations, the challenge still remains on what is the cost implication of increasing
HAART initiation. Given the fact that we are looking at quite a large number of
people living with HIV in South Africa and considering the budgetary constraints of
the country. Although studies have shown that HAART is cost-effective for people
living with HIV in South Africa, there has not been any study yet to determine if
increased early HAART initiation would still be cost-effective in the prevention of
AIDS-related malignancies. The fact that there is no known direct cause of malig-
nancies makes it difficult for one to come up with optimal prevention strategies but
knowing that for HIV-infected individuals, HAART has the ability to reduce the risk
of developing HIV-related cancers, it is thus worthwhile to look into all possibilities
of obtaining the maximum benefits that HAART could offer.
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In this chapter, we formulate a mathematical model for lymphoma progression with
HAART intervention at different CD4 cell count levels in resource limited settings.
We start off with a fully susceptible population and model the dynamics of HIV
with progression to AIDS-related lymphoma. We examine the potential impact of
initiating treatment at a CD4 cell count level of greater than 500 cells/µL or less
than 500 cells/µL to determine which option gives the best value for resources used.
We also develop and analyse a linked transmission and health state transition
(Markov) decision analysis model incorporating lymphoma incidence projections
from HIV-infected individuals with and without HAART, using TreeAge Pro 2015,
healthcare decision analysis software (TreeAge Software, Williamstown, MA, USA).
We use this model to determine the expected costs per quality of life gained (QALYs)
with HAART initiation at the two CD4 count thresholds (that is, greater than 500
cells/µL and less than 500 cells/µL) over a period of ten years.
3.2 Model Formulation
We develop a mathematical model with intervention that projects the development
of lymphoma from both HIV positive and negative individuals. Our total population
N(t), is taken to be the adult population in the range of 15 to 80 years of age. This
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is due to the fact that we are considering the sexually active population from 15 to
49 years, that is more susceptible to HIV infection. The incidence of lymphoma and
many other cancers is generally observed to be higher in individuals above the age
of 60 than the younger population. Old age is a major risk factors for developing
lymphoma and hence the choice of population age range 15 to 80.
We construct a compartmental model describing the movement of individuals from
one health state to another, starting from the susceptible class (S). Individuals
can either develop lymphoma or get infected with HIV, thus moving into the L
class or I
H
class respectively. At this stage, there is no intervention yet because
the individuals are not yet aware of their status. A proportion of individuals in the
lymphoma class then progress into the cancer therapy class (H
L
) on discovering they
have developed lymphoma (this may be through screening tests done or ill health
that necessitates seeking medical attention), while others contract HIV and move
into the class of HIV-infected with lymphoma (I
HL
). Some individuals from the
HIV-infected class (I
H
) progress into the HIV-infected with lymphoma class (I
HL
)
and others go on to start HIV treatment (HAART). We classify the HIV-infected
individuals who enrol into HAART into two classes which we will refer to as the
a and c class depending on their CD4 cell count at the time of starting treatment.
The Ic
HT
class consists of those that start treatment with a CD4 cell count of less
than 500 cells/µL and the Ia
HT
class consists of those that start treatment with CD4
cell count of greater than 500 cells/µL. A certain proportion of individuals from
the Ic
HT
class progress to the Ia
HT
class at a CD4 cell count upswing rate ξ. Some
individuals from these two classes go on to develop lymphoma and move to the class
of HIV-infected with lymphoma on HAART (I
HLT
). Some individuals from the I
HL
class also enrol into HAART and move into I
HLT
class while others go on to receive
cancer therapy without HAART, that is, move to the H
HL
class. Individuals in the
class of HIV-infected on HAART with lymphoma (I
HLT
) are enrolled into cancer
therapy at a rate ρ3. The total population N at any time (t) is thus given by;

















The intervention considered here is the initiation of HAART, which is administered
at different CD4 cell count levels to see which option is more effective in preventing
the development of AIDS-related lymphoma.
We consider different classes for treatment of lymphoma, which are; lymphoma
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therapy hospitalization for lymphoma only patients (H
L
), lymphoma therapy hospi-
talization for patients with both HIV and lymphoma without antiretroviral therapy
(H
HL
) and lymphoma therapy hospitalization for lymphoma patients with HIV and
on HAART (H
HLT
). This is done in order to account for the differences in costs
of treatment in the different categories depending on whether the patient has HIV
and is enrolled in HAART or not. Lymphoma therapy requires hospitalization for
treatment which cannot be otherwise administered at home.
In our model, there are two classes that are susceptible to HIV infection and these
are the S and L classes. We assume the same force of infection for both classes.
However, the effective contact rate of individuals in the S class will be different
from that of individuals from the L class and the rates are: β1 and β2 respectively.
The parameters βi, i = 1, 2, 3, represent the transmission risk when an HIV-infected
individual comes into contact with a susceptible person. It is the number of contacts
per unit time or the probability of an infection occurring. We have ηi, i = 1, 2, 3 as









to those in the I
H
class. The force of infection λ is

















provided λ(t) is redefined at the ε-neighbourhood of N = 0, for it to be biologically
plausible and finite at time, t = 0. The infectiousness of HIV-infected individuals
is directly proportional to their viral load. We therefore consider 0 < ηi < 1 for
i = 1, 2, 3.
The individuals in the class of HIV-infected with lymphoma and not on HAART
(I
HL
) are assumed to have a higher viral load as compared to the other infected
individuals in the other classes who are receiving HAART [26]. Also the individuals
in the Ia
HT





classes because their CD4 cell count levels are reasonably higher




. It therefore follows
that 0 < η3 < η2 < η1 < 1, meaning that individuals in the IHL class are more




, who are also more infectious than those in the
Ia
HT
class. This is due to the fact that the individuals in the Ia
HT
class have a better
immune system since their CD4 cell count is greater than 350 cells/µL and are able
to achieve some level of virologic suppression as a result of antiretroviral therapy.
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3.2.1 Model Assumptions
In our model we make the following assumptions to make it less complex and simple
enough to analyse mathematically;
1. We consider a fully susceptible population with no prior intervention and that
the population is large enough to be modelled deterministically.
2. We assume homogeneous mixing of individuals in the same compartment and
heterogeneous mixing between compartments. This means that each suscepti-
ble individual has the same probability of being infected by an individual from
an infectious class.
3. We assume that there is 80% coverage of HAART as stipulated by the South
African HIV National Strategic Plan [77].
4. We assume there is disease induced death of individuals in all classes with HIV
infection or lymphoma.
5. We assume that remission is only possible after treatment and that all patients
who undergo lymphoma therapy without HAART from the class H
HL
are im-
mediately enrolled on HAART when they go into remission and thus move to
the class of HIV-infected individuals with lymphoma on HAART (I
HLT
).
The model flow diagram for the progression of lymphoma from HIV-infected and
other susceptible individuals is as shown in Figure 3.1 below and the description of
variables and parameters used in the diagram is as given in Tables 3.1 and 3.2 that
follow respectively.
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Figure 3.1: Schematic diagram for Non-hodgkin Lymphoma progression
3.2.2 Model Equations
The dynamical system represented in figure 3.1, our assumptions, variables and
parameters are described by the following system of first order non-linear differential
equations;
Ṡ = Λ− (µ+ λ+ α1)S,
L̇ = α1S + φ1HL − (λ+ q1)L,
İ
H
= λS − (µ+ δ2)IH − (γ1 + γ2 − α2)IH ,
İ
HL
= λL+ α2IH − (γ3 + µ+ δ3 + ρ2)IHL ,
İc
HT






= γ1IH + ξI
c
HT
− (σ2 + µ+ δ5)IaHT ,
İ
HLT






+ φ2HHL + φ3HHLT − (µ+ δ6 + ρ3)IHLT ,
Ḣ
HLT
= ρ3IHLT − φ3HHLT − (µ+ δ9)HHLT ,
Ḣ
HL
= ρ2IHL − φ2HHL − (µ+ δ8)HHL ,
Ḣ
L
= ρ1L− (µ+ δ7)HL − φ1HL .

(3.2.3)
The initial conditions of the model are;











































(t) HIV-infected individuals without HAART.
L(t) HIV-negative individuals that develop lymphoma.
I
HL
HIV-infected individuals with lymphoma.
Ia
HT
HIV-infected individuals that start HAART at CD4 > 500 cells/µL.
Ic
HT
HIV-infected individuals that start HAART at CD4 < 500 cells/µL.
I
HLT
HIV-infected individuals with lymphoma on HAART.
H
L
HIV-negative individuals hospitalized for lymphoma therapy.
H
HL
HIV-infected individuals hospitalized for lymphoma therapy.
H
HLT
HIV-infected individuals hospitalized for lymphoma therapy with HAART.
Table 3.2: Description of parameters and symbols used in the Model
Parameter Description
Λ Recruitment rate of susceptibles.
µ Natural death rate.
β1 Effective transmission contact rate for S class.
β2 Effective transmission contact rate for L class.
α1 Rate of developing lymphoma by Susceptibles.
α2 Rate of developing lymphoma by IH .
λ Force of infection with HIV.
γ1 Rate of HAART initiation at > 500 CD4 cells/µL.
γ2 Rate of HAART initiation at < 500 CD4 cells/µL.
ξ Rate of CD4 cell count increase to > 500 cells/µL.
σ1 Rate of IcHT developing lymphoma.
σ2 Rate of IaHT developing lymphoma.
ρ1 Rate of seeking care and treatment for lymphoma by class L.
ρ2 Rate of seeking care and treatment for lymphoma by class IHL .
ρ3 Rate of seeking care and treatment for lymphoma by class IHLT .
φ1 Rate at which individuals in HL go into remission.
φ2 Rate at which individuals in HHL go into remission.
φ3 Rate at which individuals in HHLT go into remission.
δi(i = 1, . . . , 9) Disease induced death.
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3.3 Epidemiological Measures
Epidemiological measures are concerned with the frequency of health-related events
so as to better understand and contain health risks. The link between frequency
of occurrence of an event and the various risk factors surrounding it are put into
consideration. This is the association measure which is determined by the difference
in the rate of occurrence of a disease and the relative risk surrounding it. Here, the
frequency measure of the health event which is given by the incidence and prevalence
rate is calculated. The incidence of an event is given by the number of new cases
during a given period of time and the prevalence of an event is given by the total
number of existing cases at a given point in time. In our case disease incidence
will be determined by the basic reproduction number R0 at the HIV-disease-free
equilibrium. R0 is defined as the average number of secondary infections caused by
one infectious individual in a fully susceptible population.
3.4 Model Steady State Analysis
We analyse the model to determine the conditions necessary for the existence of an
equilibrium/steady state which we will refer to as the HIV-free lymphoma steady
state. This is the equilibrium at which the population remains in the absence of
HIV infection. In order to find this steady state, we set all terms which contain HIV















implies that the force of infection, λ = 0.
To obtain the steady state solution of the system, we set the right hand side of the
equations in system ( 3.2.3) to zero. Let the HIV-free lymphoma steady state be
denoted by E∗, this will be given by;


















Λ− (µ+ λ+ α1)S = 0, λ = 0,




letting k = α1S∗, q1 = ρ1 + µ+ δ1, q2 = φ1 + µ+ δ7, we then have,
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ρ1 + µ+ δ1












=⇒ L∗ = α1Λ
(α1 + µ)(ρ1 + µ+ δ1)
[
1 +
φ1ρ1(ρ1 + µ+ δ1)
(ρ1 + µ+ δ1)2(φ1 + µ+ δ7)− ρ1φ1
]
.
Therefore the model has an HIV-free lymphoma steady state, E∗ as given below




















3.4.1 The Basic Reproduction Number
The basic reproduction number, R0 is a threshold parameter that determines whether
the disease-free equilibrium (DFE) is stable or otherwise. If R0 < 1 , then the DFE
is locally asymptotically stable, which means that the disease will eventually die out
because there is not enough new cases generated to keep the infection in the popula-
tion. While, if R0 > 1 , the DFE is unstable, which means that there is a likelihood
that an epidemic will occur in the population since each infectious individual is able
to produce more than one secondary case of infection in the population [36, 38].
However, a disease may persist even though the DFE is locally stable [38]. In the
presence of an intervention, we have Re, which is known as the effective reproduction
number.
The effective reproduction number of our model is calculated using the next gen-
eration matrix method (Watmough and Van den Driessche [38]). We first find the
matrix representing new infections, F and the matrix representing progression of
infection, V , from our system of equations (3.2.3).
In this model, we assume that all individuals under lymphoma therapy are hospi-
talised. Therefore lymphoma patients who are HIV+ are not able to transmit the
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βq βη1q βη2q βη3q βη2q
βw βη1w βη2w βη3w βη2w
0 0 0 0 0
0 0 0 0 0





g1 0 0 0 0
−α2 g2 0 0 0
−γ2 0 g3 0 0
−γ1 0 −ξ g4 0
0 −γ3 −σ1 −σ2 g5

(3.4.2)
where , g1 = γ1 + γ2 +α2 +µ+ δ2, g2 = γ3 + ρ2 +µ+ δ3, g3 = σ1 + ξ+µ+ δ4,
g4 = σ2 + µ+ δ5, g5 = ρ3 + µ+ δ6.
The next generation matrix for the infected subsystem of the model system (3.2.3)
is given by the product FV −1, calculated at the disease free equilibrium and thus
the spectral radius of R0 is given by;
R̂0 = ρ(FV
−1).
The model reproduction number , Re (effective reproduction number due to presence
of treatment as an intervention) was found to be a combination of contributions from
the different infected classes in the model and is the sum of the reproduction numbers
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The reproduction number, RIHe = qβg1 is a product of the rate of progression of in-
dividuals into the I
H
class and their average duration of stay in that class. RIHe is
therefore the average number of new infections caused by a single infectious individ-
ual during their stay in the I
H
class, in a fully susceptible population.
On the other hand, the reproduction number RIHLe is a sum of two terms which
represent the different ways in which individuals that come to that class contribute














The term denoted by X represents the average duration of infectivity of individuals




HIV-infected individuals from the I
H
class that develop lymphoma and progress to
the I
HL
class, while the term denoted by Z represents the contribution to RIHLe by
individuals originally with lymphoma from the L class who get infected with HIV
and progress to the I
HL
class. The same logical explanation follows for all the other
reproduction number cases presented in (3.4.4) above.
A more specific definition of Re in the context of our model is the number of new
secondary cases of infection produced by an HIV-infected individual (regardless of
whether he/she has developed lymphoma and is under antiretroviral therapy or not)
when they are introduced in a wholly susceptible population.
However, the basic reproduction number (R0) for our model can be obtained by










e will all go to zero because they are from the classes of indi-
viduals receiving antiretroviral therapy as an intervention. Therefore our R0 will be
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3.4.1.1 Comparison of the Reproduction Numbers
We compare the reproduction numbers of the model using Matlab to determine how
each reproduction number varies as the transmission contact rate (β) changes.





































Figure 3.2: The correlation between the effective reproduction numbers
and contact rate (β).
In Figure 3.2, the variables Re1, Re2, Re3, Re4 and Re5 represent the reproduction












e respectively. The figure provides a com-
parison of the different effective reproduction numbers with respect to the contact
rate (β) as it varies between 0 and 1. We observe that as β increases the following
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This means that the infectiousness of individuals in the classes without intervention
is much higher than that of individuals in the classes with intervention as their
contact rate increases. From this observation we can deduce that intervention at a
CD4 cell count greater than 500 cells/µL is more effective at reducing HIV infection
and therefore reducing the prospect of developing AIDS-related malignancies.
We conclude therefore that the transmission contact rate has a substantial effect
on the reproduction numbers. With the presence of interventions, the incidence of
HIV infection is reduced but early intervention at a CD4 cell count of greater than
500 cells/µL is more effective in reducing the reproduction number as compared to
intervention at a CD4 cell count level of less than 500 cells/µL.
3.5 Incidence and Mortality
The incidence of lymphoma in HIV positive individuals is largely due to a severely
suppressed immune system. The survival rate of people with non-Hodgkin lym-
phoma (NHL) varies widely and depends on the number of risk factors affecting
the individual such as age (60+) at time of onset of the disease, extra-nodal sites of
the disease, an arbor stage III/IV, Lactate dehydrogenase (LDH) greater than the
normal upper limit, among others [4]. Individuals with more than three risk factors
have a higher mortality rate than those with one or less risk factors. According to
the American cancer society, the relative survival rate for patients with NHL is 67%
for 5 years and 55% for 10 years [4].
3.5.1 Lymphoma Incidence
The incidence of lymphoma in our model is determined by the CD4 cell count of
individuals at the time of treatment initiation. The individuals that enrol into
treatment at an early stage have less chances of developing lymphoma. Therefore
lymphoma incidence depends on the parameters α1, α2, σ1, σ2 and γ1, the rate at
which individuals start treatment at CD4 cell count greater than 500 cells/µL.
The population considered to be at risk of developing lymphoma according to our
model are the Susceptibles (S), HIV-infected individuals not on HAART (I
H
) ,
individuals enrolling on HAART at CD4 count greater than 500 cells/µL (Ia
HT
) and
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incidence of lymphoma will therefore be given by the following function;
Incidence =









where α1, α2, σ1 and σ2 are the rates at which individuals in the S, IH , IcHT and I
a
HT
classes respectively, develop lymphoma. We use γ1 as the preferred initiation rate
since the recommendation for reducing lymphoma incidence is a higher CD4 count
threshold.
Figure 3.3: Correlation between lymphoma incidence and HAART ini-
tiation rate (γ1).



















In plotting the incidence function against the rate of HAART initiation γ1, we see
that as initiation increases, the incidence of lymphoma decreases. We also observe
that it would be possible to eliminate lymphoma through increasing HAART initi-
ation at CD4 count greater than 500 cells/µL to above 80% coverage. This would
meet the requirement for elimination of HIV transmission according to the South
African HIV National Strategic Plan 2012 [77]. Therefore, increasing early therapy
initiation would not only reduce the transmission and incidence of HIV but also
prevent AIDS-related lymphoma.
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3.5.2 Mortality
The mortality rate due to lymphoma in our model will depend on the total number
of deaths due to lymphoma in the ten-year period under consideration and the
population at risk of death due to lymphoma which are the individuals in the classes
that have lymphoma. Mortality rate will therefore be given by the following function;
Mortality =












Plotting mortality against early HAART initiation rate, γ1, in Figure 3.4, we see
that as the rate of early initiation increases, mortality rate decreases. This result
indicates that early HAART initiation could be effective in reducing lymphoma-
related deaths.
Figure 3.4: Correlation between mortality rate and early initiation rate
(γ1).























We measure the costs associated with each intervention strategy by reviewing the
program’s financial and services records in order to quantify the resources used,
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associated costs and clients served. We then compare the costs for every alternative.
Individuals accumulate costs as they move through the model cycles and these costs
are associated with the event and outcomes at each stage. These costs comprise
of direct medical costs which include screening costs, diagnostic tests and costs for
lymphoma therapy. Costs for HIV care and treatment are informed by literature
and include both inpatient and outpatient care.
In South Africa, the costs of lymphoma treatment and diagnosis are very high and
are mainly subsidised by medical insurance and the government. However, data
on lymphoma healthcare costs is not readily available, therefore we use estimates
derived from similar studies and costs of HAART are informed by previous studies
carried out in Southern Africa [8, 46].
We assume that screening for HIV is done twice a year and screening for lymphoma
is done once a year for HIV-infected individuals. Screening costs are associated with
the fraction of susceptible individuals who choose to go for HIV testing and individ-
uals from the HIV class that get screened for lymphoma, then also lymphoma only
patients from the L class that go for HIV screening. We denote the cost of screening
for HIV and lymphoma by Cs1 and Cs2 respectively (also includes costs of delivering
screening tests). The annual cost of initiating HAART at CD4 count greater than
500 cells/µL denoted by Ca is associated with the proportion of individuals in the
Ia
HT
class from the I
H
class whose CD4 cell count is greater than 500 cells/µL at the
time of enrolling on HAART. The annual costs of initiating HAART at CD4 count
less than 500 cells/µL denoted by Cc are associated with the proportion of HIV-




that enrol onto HAART with a CD4
cell count of less than 500 cells/µL. Cc also includes costs of treating opportunistic
infections that arise with low CD4 cell count due to immunosuppression. The cost of
increasing HAART coverage denoted by Cp is proportional to the number of people
that enrol on HAART irrespective of their CD4 cell count. The cost of enrolling
lymphoma patients who get infected with HIV on HAART denoted by Cl is associ-
ated with the proportion of individuals from the I
HL
class who enrol on HAART and
are in the I
HLT
class. Ch denotes the costs that are associated with treatment, care
and hospitalization for patients who have developed lymphoma and are receiving
lymphoma therapy. Cf denotes the costs of follow up which are associated with
individuals in the classes I
HLT
and L who are in remission after lymphoma therapy.
Cf also includes costs on follow-up tests and doctors’ visits.
The costs indicated here are representative of healthcare expenditure on individuals
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in a particular disease stage measured annually. Therefore, the overall cost rate
function in US dollars denoted by C(t) at time t, is given by the following equation.

























The total costs accumulated over 10 years are calculated by summing up all costs
incurred in each health state over the entire period of time.
3.6.2 Discounting
In cost-effectiveness analysis, it is important to discount all costs in order to account
for all future costs in terms of the net present-day value [63, 72]. Costs and health
benefits accrued in future are worth less than those accrued at present. Discounting
is usually done to account for inflation that will affect accuracy in measuring future
costs. All costs and health events are discounted to the year 2015 at a rate (r)
of 5% per annum, which is consistent with that used in previous studies done in
Southern Africa [52]. We use cumulative costs to calculate average costs per annum
for the entire period of study. Therefore, the total discounted costs over 10 years







Decision analysis is the process of making informed and objective decisions in the
presence of a complex situation. This process involves decision structuring tech-
niques, assessment of alternatives, quantifying uncertainties and evaluating options
in order to determine the best alternative under the given circumstances. Decision
analysis is facilitated by statistical tools such as decision trees, multivariate analysis
and probabilistic forecasting which are applied to mathematical models of real-life
situations in order to determine the course of action that best suits the situation
giving the best value for resources used.
With the increasing costs of healthcare today, it has become inevitable for policy-
makers, clinicians and researchers to use decision-analysis modelling in addressing
this challenge. Decision analysis involves making a decision in uncertain circum-
stances. In the case of our model, we need to decide on whether it is more beneficial
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to initiate HAART at CD4 count less than 500 cells/µL or greater than 500 cells/µL.
We want to determine the costs of each intervention option in relation to its effec-
tiveness in preventing lymphoma. In this regard, we carry out cost-effectiveness
analysis of initiating HAART at the different CD4 cell count thresholds. We con-
struct a decision tree in TreeAge Pro in order to estimate the expected costs and
health benefits (life years gained) of initiating HAART at the two CD4 cell count
thresholds and the impact of each alternative on the incidence of lymphoma. In this
study, our base case is; determining when to initiate HAART and the decision lies
between initiating treatment at CD4 count less than 500 cells/µL or at CD4 count
greater than 500 cells/µL as illustrated in Figure 3.5 below. The nodes marked m1
and m2 are markov nodes.
When to start treatment
m1
m2
Start at CD4 < 500
Start at CD4 > 500
Figure 3.5: The base case and decision
Markov nodes and the cycle sub-trees that follow represent markov processes. We
take the length of each cycle in the markov model to be one year. In a markov
process it is assumed that the behaviour of individuals in the system only depends
on their current health state and transition probabilities. We use markov modelling
here because of the continuous risk of re-occurrence of lymphoma over time. When
lymphoma patients undergo first-line treatment and recover, there is a likelihood
that they could relapse later on and have to take second-line treatment. This sce-
nario is common in patients who are initially diagnosed with indolent (low-grade)
lymphoma because its chances of being completely eliminated are low. Patients with
advanced low-grade lymphoma are likely to have a relapse more than once in their
lifetime. The recurrence of lymphoma is likely to take place in the same area of the
body as previously affected or it could recur in another place [56, 57].
Figure 3.6 is a representation of the markov processes in our model for the No-
HAART and HAART scenarios. The model is comprised of six health states, each
of which incorporates the natural history of HIV, AIDS-related lymphoma with
and without antiretroviral therapy. It is assumed that patients with lymphoma
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are given lymphoma therapy before going into remission and those with HIV and
lymphoma without HAART could either first enrol into HAART or first receive
lymphoma therapy before enrolling into antiretroviral therapy. It is also assumed













Figure 3.6: Markov state transition diagram
The decision tree in Figure 3.7 illustrates the modelling process involved in decision
analysis of initiating HAART at two different CD4 cell count levels (The full decision
tree build up is as shown in Figure 4.1). In the diagram, RX and No RX repre-
sent treatment and no treatment respectively. The model structure is a collection
of nodes which are chronologically arranged to relay decisions and events from the
original decision to all possible scenarios for each option taken. We start with pa-
tients who are HIV-positive and use CD4 cell count as a threshold to determine the
proportion of individuals who can start treatment as stratified by the current policy
in place, then we follow all individuals through a markov process to developing lym-
phoma, then end up in a certain health state or die. We use transition probabilities
for individuals to move from one stage to another and conditional statements for
logical decisions at the logic node (the initiation policy determines the proportion
of individuals taking each path at this node, there is no free will for individuals to
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make a choice). We attach costs and utilities at each stage in order to be able to
determine effectiveness at each path and compare the different options.
Figure 3.7: Example of Decision Tree model diagram
Each of the nodes in the decision tree represents a different course of action that
has to be taken voluntarily or involuntarily.
The decision node (with a square shape) indicates a choice that is under the control
of individuals that make decisions such as policy makers. The chance node (circular
in shape) represents events that may occur beyond the control of decision makers
and are associated with the probability of subsequent events. The terminal nodes
which are triangular in shape represent the end point/terminal point of a process
and these are normally assigned payoff values. Each terminal node represents the
entire path from the root node to that terminal node. The branches from each node
represent possible events that follow consequently. Hence, branches from decision
nodes represent the actions/strategies under consideration, these may not be mutu-
ally exclusive. The branches from chance nodes represent probable outcomes from
that event, these should be mutually exclusive and exhaustive with a probability
sum of one. A Markov node on the other hand normally has several branches orig-
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inating from it, representing each of the health states involved in the process and
each branch connects to a cycle tree/sub-tree which reflects all the events that oc-
cur during that cycle. The probability at each markov branch represents the initial
proportion of individuals in each health state. Attached to each markov branch is
an incremental utility that represents one cycle’s value of being in that state. The
terminal nodes in markov models are set to one of the markov states and are also
called "jump states". These jump states indicate what state to go to in the next
cycle. Unlike in other decision trees, in markov models outcomes are not defined
at the terminal node due to the fact that they are jump states. The dead state
however, is an absorbing state and thus has no branches emerging from it.
In this tree analysis, we want to investigate the cost impact of initiating HAART
at different CD4 cell count levels on lymphoma incidence and the quality of life
of individuals. We start off with a population of HIV-infected individuals. The
decision to be made initially is on when to start antiretroviral therapy. There are two
options to choose from, which include, starting treatment at a CD4 count less than
500 cells/µL or at CD4 count greater than 500 cells/µL. Therefore all individuals
diagnosed with HIV have to be classified according to their CD4 cell count (which is
usually done by flow cytometry) in order to determine whether they meet the criteria
for starting antiretroviral therapy at that node. Depending on the policy in place,
the decision will lead to one of the two branches of scenarios for starting treatment.
This initial position (the decision) for all cases in the model cannot be repeated.
Once the decision has been established we follow the patients through a markov
modelling process. It is important to note that the sub-tree and consequently the
order of events in the markov clone at the node "start at CD4 > 500" is an exact
replica of the markov sub-tree at the node "start at CD4 < 500" and the difference
between the two is the probability at which events occur and the effectiveness of
treatment at each health state. These variables are defined at each of the markov
nodes for each of the markov processes. We assume that the CD4 count of all
patients that start treatment increases by 50 cells/µL in the next stage and reduces
by 50 cells/µL with no treatment in the subsequent stages. Therefore we use the
functions;
CD4 = CD40 + stage× 50 for increasing CD4 count,
CD4 = CD40 − stage× 50 for declining CD4 count,
where, CD40 represents the CD4 count at the previous stage.
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At the logic node we enter a condition that is tested before proceeding to either of
the branches. In our analysis we used the following conditional statement which is
an if function;
I if (condition; true value; false value):
where, the condition is threshold for treatment initiation, and the true value
is the probability of starting treatment at either one of the two markov nodes.
Results and Findings
From the model analysis in Treeage, the cumulative discounted costs at CD4 less
than 500 for a period of tens years were as indicated in Figure 3.8 and the discounted
cumulative effectiveness for the same period was as indicated in Figure 3.9 below.
From the figures, we see that there is a rapid increase in costs associated with
Figure 3.8: Cumulative costs at CD4 less than 500.
initiating HAART at CD4 count less than 500cells/µL. Cumulative costs rise from
nearly $2,000 at the beginning to about $24,200 at the termination stage of the
model. Cumulative effectiveness on the other hand increases from about 0.3 at the
start to about 2.7 at the end of the 10 years. This implies that the cost per unit of
effectiveness would be approximately $9,250 which is quite high and not desirable.
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Figure 3.9: Cumulative Effectiveness at CD4 less than 500.
Figure 3.10: Cumulative Costs at CD4 greater than 500.
Figure 3.10 and 3.11 show that with HAART initiation at CD4 count greater than
500 cells/µL, cumulative costs will increase from $2,000 to about $38,800 and cumu-
lative effectiveness will also increase from about 0.3 to about 6.4. Although there is
a higher increase in cost in this strategy than the alternative, the resulting increase
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Figure 3.11: Cumulative effectiveness at CD4 greater than 500.
in effectiveness is more than twice as much as that of the alternative and would thus
be a more desirable outcome. Further, looking at the cost-effectiveness analysis of
each strategy we see that both strategies lead to increased effectiveness in terms of
life years gained, but there is a remarkable increase in the costs as well. Therefore,
neither of the two strategies is dominated but one exceeds the other in terms of the
resulting health outcomes and thus makes it more favourable. An intervention can
be taken to be cost-effective if it more costly and more effective at the same time,
which is what we see in this case.
The graph of cost-effectiveness results Figure 3.12 clearly shows the difference be-
tween the two strategies. The costs and effectiveness of initiating HAART at CD4
count greater than 500 cells/µL are much higher than initiation at CD4 count less
than 500 cells/µL the base case. This indicates that the former is more cost-effective
than the base case since it is more efficient in improving health resulting in more
life years gained.
The results of Markov modelling are as displayed in the Figures 3.13 and 3.14 rep-
resenting HAART initation at CD4 less than 500 cells/µL and at CD4 greater than
500 cells/µL respectively. We considered six possible health states and the entire co-
hort is HIV-infected initially. The health states that follow are the possible states in
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Figure 3.12: Cost-effectiveness results graph.
























Figure 3.13: Markov state probability at CD4 less than 500 cells/µL
which individuals could be with time as some of them progress to developing AIDS-
related lymphoma. Costs and utilities are attached to these health states in order
to calculate the cost-effectiveness of each strategy. The health states considered are
as described in Table 3.3.
The probability that an HIV-infected individual will be in any of the six health
states at a given time within the ten-year time period is displayed in Figures 3.13
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Figure 3.14: Markov state probability at CD4 greater than 500 cells/µL
Table 3.3: Markov health states
State Definition
HIV state with HIV, no HAART and no lymphoma.
HIV.Trtmt state with HIV, HAART and no lymphoma.
HIV.lymphoma state with HIV, lymphoma and no HAART.
HIV.Trtmt.lymphoma state with HIV, HAART and lymphoma.
HIV.Trtmt.remission state with HIV, HAART and in remission.
Dead the death state.
and 3.14 depending on their CD4 count at the time of HAART initiation. The peaks
in the figures indicate the time when individuals in the cohort are at the highest
risk of being in that state. In Figure 3.13, we see that halfway through the process,
individuals who are to start antiretroviral therapy at a lower CD4 count are more
likely to have developed lymphoma or be dead. At the end of the process we see
that there are higher chances of an individual having lymphoma without treatment
and also with treatment as compared to the probability of reaching the final stage
without having lymphoma. With time as CD4 count depreciates, individuals will be
eligible to start HAART and therefore progress to a state with treatment. However,
we see that the proportion of those that develop lymphoma without treatment is
still slightly greater than that of individuals that develop lymphoma with treatment.
In Figure 3.14, we observe that the state probability of HIV.Trtmt stands out,
indicating that initiating HAART at CD4 count greater than 500 cells/µL is highly
effective. From the figure, we can also see that there is a greater chance of an
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individual in our cohort existing in the above mentioned health state than in any of
the other states due to early antiretroviral treatment initiation. It is also imperative
to note the low rate of deaths and individuals that have lymphoma or are in remission
with early HAART initiation. Also in Figure 3.14, we see that the two health states
with no treatment (HIV and HIV.lymphoma) go to and remain at zero probability
before the second year. This can be explained by the fact that the condition for
initiating treatment will ensure that all individuals enrol into treatment early enough
before their CD4 count depreciates. This leads to an increased (or stable) CD4
count above the threshold that always meets the criteria for treatment initiation
throughout the entire period of 10 years considered in the model.
Figure 3.15: Survival/non-survival at CD4 less than 500 cells/µL
The survival and non-survival curves in Figure 3.15 indicate that the probability
of an individual who started HAART treatment at CD4 less than 500 cells/µL will
die in 10 years is higher than the probability that they will survive. Therefore, this
strategy may not be effective in improving the health and livelihood of individuals.
On the other hand, the curves in Figure 3.16 indicate a big gap between survival
and non-survival of individuals that start HAART treatment at CD4 count greater
than 500 cells/µL. The probability of surviving with early initiation is much higher,
at a rate of approximately 80%, than the probability of dying approximated at 20%.
Therefore individuals that start treatment early are more likely to live longer than
the ones that start later. Figure 3.17 clearly shows the distinction in survival between
the two initiation strategies. From the above results, we can conclude that early
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Figure 3.16: Survival/non-survival at CD4 greater than 500 cells/µL
HAART treatment initiation has a higher survival rate than the alternative and is
therefore effectiveness in reducing the mortality rate of HIV-infected individuals and
promoting quality of life.

















Figure 3.17: Survival at CD4 greater than 500 cells/µL vs. survival at
CD4 less than 500 cells/µL
Costs used for modelling are mainly inferred from existing literature and all future
costs are discounted to the year 2015/2016. All costs are presented in US dollars
($). Health care costs were attached to health states from the public health care
perspective. In most cases patients are seen by a general practitioner at primary
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Table 3.4: Clinical event parameters used in Decision Analysis
Variable Value (%) Range (%) Reference
Probability of starting HAART at CD4 < 500 40 10 - 60 assumed.
Probability of starting HAART at CD4 > 500 65 40 - 80 assumed.
Probability of developing NHL without HAART 56 10 - 80 [18]
Probability of developing NHL with HAART at CD4 < 500 41 10 - 60 [18]
Probability of developing NHL with HAART at CD4 > 500 33 10 - 50 [18]
Probability of remission with HAART 50 10 - 60 assumed.
Probability of remission without HAART 30 01 - 40 assumed.
Probability of relapse without HAART 95 40 - 100 assumed.
Probability of relapse with HAART 45 01 - 50 assumed.
Probability of HIV death while on HAART 0.1 0.01 - 0.4 assumed.
Probability of lymphoma death without HAART 0.2 0.01 - 0.4 assumed.
Probability of lymphoma death with HAART 0.1 0.01 - 0.4 assumed.
Probability of HIV death without HAART 0.2 0.01 - 0.6 assumed.
Probability lymphoma persists with HAART 15 02 - 25 assumed.
Probability lymphoma persists without HAART 76 50 - 99 assumed.
Probability of death in remission 0.3 0.1 - 1.0 assumed.
HIV prevalence 17.9 17.2 - 18.2 [8]
Total cycles 10 10 assumed.
care level before going to a secondary level hospital for treatment according to the
public health system. Some of the costs used in the analysis were inferred from the
Western Cape public hospital tariff schedule [86]. Medical services costs are also
included in healthcare cost calculation because they represent the monetary value
of patient care.
Table 3.5: Health care cost estimates
Costs Value (US$) Reference
Cost of GP visit 32 [86]
Annual cost of HIV screening per person 22 [46, 52]
Annual cost of Lymphoma screening 105 [44]
HIV care costs at CD4 < 500 14,000 [46]
HIV care costs at CD4 > 500 14,600 [46]
Lifetime medical care costs for HIV 8,000 [55]
Cost of diagnostic biopsy 105 [44]
Cost of patient follow up per annum 69 [44]
Annual cost of lymphoma therapy 6,000 estimated.
Annual Cost of HAART per patient 113 [83]
Discount rate 5% [52]
A summary of the cost-effectiveness results is as shown in the Table 3.6 below;
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3.7.1 Sensitivity Analysis
In order to determine the ICER variations with key parameter changes, sensitivity
analysis was carried out. One-way sensitivity analysis was done on event probabil-
ities, costs and utilities to determine the impact of their uncertainty on the final
results of cost-effectiveness analysis. The tornado plot in Figure 3.18 shows results
of one-way sensitivity analysis, indicating how the outcomes are affected by some
of the model input parameters. The tornado plot is stacked according to decreas-
ing width with parameter inputs at the top displaying the greatest influence on
outcomes and changes in parameter inputs close to the bottom exhibiting less in-
fluence on the outcomes. Sensitivity analysis results showed that outcomes were
most sensitive to the effectiveness of HAART in preventing lymphoma incidence,
with early initiation at CD4 count greater than 500 cells/µL, exerting the greatest
influence on net benefits and the ICER outcomes than the base case. Most of the
parameters, except for the ones indicated in the tornado plot with a certain degree
of uncertainty, did not have notable influence on cost-effectiveness analysis results
and are thus considered to be neither value nor decision sensitive. More information
pertaining to the parameters indicated in the sensitivity analysis tornado plot is
required in order to ascertain their actual impact on the results of cost-effectiveness
analysis. The effectiveness of HAART, in the absence of lymphoma, displayed the
widest range of uncertainty and therefore there is more information required on this
utility than the other parameters displayed therein for further clarification on the
results of the model analysis. From the tornado plot results, we can also deduce
that a higher value of HAART without lymphoma utility could lead to increased
net benefits.
3.8 Conclusion
In this chapter, we developed a health state transmission model to predict the inci-
dence of AIDS-related lymphoma in a population of age range 15 to 80 years and also
a decision analysis Markov state transition model to determine the cost-effectiveness
of early HAART initiation. The model described the progression of individuals from
health states with HIV and incorporated HAART initiation at different CD4 counts
of greater than 500 cells/µL and less than 500 cells/µL. The results of the model
analysis indicated that HAART initiation at a higher CD4 count is more effective in
reducing the incidence of HIV (as shown by comparison of the effective reproduction
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Utility, HAART without lymphoma (0.1-7.0)
Utility, HAART in remission (0.1-6.0)
Utility, HAART with lymphoma  (0.1-5.0)
Utility, HAART at CD4 > 500  (0.1-1.0)
Probability lymphoma persists with HAART (0.1-0.7)
Probability of developing lymphoma with HAART at CD4 < 500
(0.01-0.6)
Probability of remission (0.01-0.6)
Probability of developing lymphoma with  HAART at CD4 > 500
(0.01-0.4)
Probability lymphoma persisting without HAART (0.0-0.78)
Discount rate (0-5%)
Net Benefits
Figure 3.18: Tornado plot of one-way sensitivity analysis
numbers in Figure 3.2), and thereby preventing the incidence of AIDS-related lym-
phoma. This implies that preventing further spread of HIV, the greatest risk factor
for AIDS-related malignancies, leads to prevention of AIDS-related lymphoma. Re-
sults also indicated that the rate of HAART initiation has an effect on the incidence
of AIDS-related lymphoma (Figure 3.3). The incidence of lymphoma decreases with
increase in the rate of HAART initiation, and increasing the rate of initiation to
above 80% could potentially lead to no lymphoma incidence at all. With the deci-
sion analysis model, we were able to determine and compare the expected costs, net
monetary benefits and quality of life gained with HAART initiation at CD4 count
greater than 500 cells/µL and at CD4 count less than 500 cells/µL, the current stan-
dard of care. The model is run over a 10-year time horizon and the outcomes are
discounted at a rate of 5% as recommended in Southern Africa. Results from this
analysis indicated that the costs of HAART initiation at CD4 count greater than
500 cells/µL would be higher than the costs of initiation at CD4 count less than
500 cells/µL by approximately $14,613 over 10 years. The net monetary benefit of
early initiation as compared to the alternative would be $60,518 and the QALYs
gained with early initiation would be 6.47 as compared to 2.71 for the alternative.
From the results we can deduce that early HAART initiation at CD4 count greater
than 500 cells/µL is more cost-effective than the alternative with an incremental
cost-effectiveness ratio of $3,890 per QALY gained. Sensitivity analysis carried out
on the model parameters indicated that the results were highly sensitive to the ef-
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fectiveness of HAART in preventing lymphoma, and the effectiveness at CD4 count
greater than 500 cells/µL was more sensitive than the alternative. Therefore, in-
creased early initiation of HAART is not only effective but also cost-effective in
preventing AIDS-related lymphoma in resource limited settings.
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Discussion and Conclusion
This study, to the best of our knowledge, is the first attempt at modelling HAART
initiation as prevention of AIDS-related lymphoma and its associated cost-effectiveness
in South Africa. We have assessed the effectiveness and cost-effectiveness of initiat-
ing HAART at two CD4 cell count thresholds. Using a mathematical model for the
dynamics of HIV progression with treatment initiation at two CD4 cell count levels,
we were able to assess the impact of early antiretroviral therapy on the progression
of HIV and development of lymphoma. We used a system of ordinary differential
equations to analyse and understand the dynamics of disease progression among in-
dividuals in the different compartments. We found that early initiation of HAART
at CD4 count greater than 500 cells/µL was more effective in preventing HIV pro-
gression and hence the development of lymphoma in HIV-infected individuals. The
analysis of the basic reproduction number, R0 showed that individuals that started
treatment at a lower CD4 cell count and those with lymphoma were more likely to
increase the spread of HIV than those that started treatment early.
We analysed the cost-effectiveness of HAART initiation at CD4 count greater than
500 cells/µL and at less than 500 cells/µL using a decision tree with markov pro-
cesses in Treeage pro. The model was run over a time period of 10 years with a
hypothetical cohort. From the analysis we found that early HAART initiation in
HIV-infected individuals would provide greater value than the alternative and would
be cost-saving in the long run with monetary benefits of $90,581 as compared with
$30,063 of the alternative. Sensitivity analysis results showed that our model was
sensitive to the effectiveness of HAART in preventing lymphoma and especially the
effectiveness of early treatment initiation. There were more benefits in terms of qual-
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ity of life gained with early initiation than the alternative (6.47 QALYs expected for
initiation at CD4 count greater than 500 cells/µL versus 2.71 QALYs for initiation at
CD4 count less than 500 cells/µL). From our model we could deduce that treatment
initiation at CD4 count greater than 500 cells/µL could lead to improved quality of
life translating to 3.76 QALYs in 10 years. The cost of early initiation increased by
$14,613 in comparison to the alternative. Therefore early initiation of HAART at
CD4 count greater than 500 cells/µL was cost-effective with an incremental cost-
effectiveness ratio (ICER) of $3,890 per QALY gained. This analysis showed that
there’s more to gain by increasing early HAART initiation for all people infected
with HIV in terms of costs and improved quality of life. However, the long-term
impact of highly active antiretroviral therapy on AIDS-related lymphoma incidence
still remains unknown and further research needs to be done in order to ascertain
this. TreeAge Pro software (particulary the Healthcare module) has been a very
helpful tool in the modelling and analysis of our model. The use of TreeAge pro in
cost-effectiveness analysis is highly recommended as the software helps one easily
build decision trees for better understanding of the stages and processes of analysis
bringing to light more factors that go into the process of decision analysis.
As reported by other studies on the effectiveness and cost-effectiveness of HAART
[11, 25, 46, 48, 65], our study also showed that early treatment initiation is effective
in preventing further HIV progression and possibly forestalling AIDS-related lym-
phoma. Given that maximum coverage of early HAART initiation and complete
adherence to treatment by all HIV-infected individuals is achieved, HIV and AIDS-
related lymphoma would significantly reduce thus leading to savings on costs that
would have been incurred on treatment of new cases and advanced disease stage that
are more costly. This deduction however, needs to be verified by a clinical study
with actual figures for all variables used in the model to ascertain the real impli-
cation of increasing HAART initiation to CD4 count greater than 500 cells/µL on
lymphoma incidence and the associated cost-effectiveness. The late commencement
of antiretroviral therapy is largely attributed to low rates of HAART coverage and
initiation policy decisions that do not favour early commencement of treatment by
all HIV-infected individuals. With a revised initiation policy in place, we should be
able to see a notable decline in incidences of HIV and AIDS-related lymphoma in
South Africa. This would also mean an improvement in the quality of life of people
living with HIV and a reduced burden on the government economy as HIV and its
related illness have been greatly affecting South Africa’s economic growth. However,
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there are several challenges of adherence to treatment that need to be addressed in
order to achieve maximum benefits from a given treatment initiation strategy.
Limitations
The main limitation to CD4-count driven modelling of AIDS-related lymphoma
is the lack of patient records on CD4 count history prior to lymphoma diagnosis.
Records only show CD4 count measurements taken at the time of lymphoma diag-
nosis. The only data available to us currently is that of incidence and prevalence of
HIV-related lymphoma in South Africa from 2002 to 2012 [1, 6] shown in Table 4.1.
Table 4.1: Number of lymphoma cases per year as recorded by TLSG
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
HIV-infected 2 15 17 16 35 43 43 48 32 53 55
Non-HIV-infected 33 106 95 62 147 133 150 131 150 185 144
Total 35 111 112 78 182 176 193 179 182 238 194
Although we were able to construct a model for cost-effectiveness analysis, we were
unable to find comprehensive records on the costs of lymphoma diagnosis, treatment
and care in HIV patients because such records are not readily available and therefore
the parameter values used for evaluation in this study are estimates from similar
studies.
Conclusion
As it stands, the cause of lymphoma is not yet established and therefore prevention
of lymphoma largely depends upon reducing conditions that lead to the increased
risk of developing malignancies such as immune suppression in HIV-infected indi-
viduals [13? ]. Given the level of complexity of cancer epidemiology, it is difficult to
determine the actual extent to which HAART could actually prevent AIDS-related
lymphoma. However, the cost of cancer treatment and end of life care is much
higher than the cost of increasing HAART initiation. Therefore, with the increasing
burden of HIV and cancer in South Africa, our analyses suggest that early HAART
initiation, increased coverage, routine screening for cancer and reduction in risky
behaviours should be emphasised in order to prevent lymphoma in HIV-infected
individuals.
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4.1. Future Research Recommendations
4.1 Future Research Recommendations
This model can be extended to include demographic factors such as age, sex, race,
geographical location (rural or urban settings) and income status of individuals. A
cost-benefit analysis (CBA) could be carried out to asses whether the benefits of the
intervention exceed its costs. However, it is important to note that in carrying out a
CBA, expressing healthcare benefits in terms of their monetary value can be rather
difficult and the process can be very complex and expensive to undertake. There are
concerns with treatment resistance in some patients and this can also be considered
in modelling the effectiveness of HAART in prevention of lymphoma [58].
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In this section we present the breakdown of the decision tree model constructed
in TreeAge Pro 2015 (TreeAge Software, Williamstown, MA) which was used to
evaluate the cost-effectiveness of HAART initiation at two CD4 cell count levels.
Figures 4.2, 4.3, 4.4, 4.5 and 4.6 below show a breaking down of the sub-trees at
each of the markov states indicated in fig 3.7 for a clear view of the processes that
follow from each health state.
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Figure 4.1: Complete Decision Tree diagram
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Figure 4.2: Sub-tree at Markov state HIV+no RX+no lymphoma
Figure 4.3: Sub-tree at Markov state HIV+no RX+lymphoma
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Figure 4.4: Sub-tree at Markov state HIV+RX+lymphoma
Figure 4.5: Sub-tree at Markov state HIV+RX+nolymphoma
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Figure 4.6: Sub-tree at Markov state HIV+RX+remission
65
Stellenbosch University  https://scholar.sun.ac.za
List of References
[1] Abayomi, Akin E. , et al. "Impact of the HIV epidemic and anti-retroviral treat-
ment policy on lymphoma incidence and subtypes seen in the Western Cape of South
Africa, 2002-2009: preliminary findings of the Tygerberg Lymphoma Study Group."
Transfusion and Apheresis Science 44.2 (2011): 161-166.
[2] Adam, Muhammad A., et al. "Estimation of adult antiretroviral treatment coverage
in South Africa." South African Medical Journal 99.9 (2009): 661-667.
[3] Achenbach, Chad J., et al. "Mortality after cancer diagnosis in HIV-infected indi-
viduals treated with antiretroviral therapy." AIDS (London, England) 25.5 (2011):
691.
[4] American Cancer Society."Survival rates and factors that affect prognosis (outlook)
for non-Hodgkin lymphoma." Available at: http://www.cancer.org/cancer/non-
hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-factors-prognosis.
2015, online; accessed September, 2015.
[5] National Institute of Allergy and Infectious Diseases (NIAID)."Variations in response
to HIV exposure and infection." Available at:https://aidsinfo.nih.gov/news/
106/variations-in-response-to-hiv-exposure-and-infection-long--term-
survivors-and-others. June 1993. Accessed 1 September, 2015.
[6] Akinlotan Morenikeji.D. "Modelling the dynamics of HIV-related malignancies." Stel-
lenbosch University masters thesis 2013.
[7] Aleem, Ilyas S., et al. "What is a clinical decision analysis study?." Indian journal of
orthopaedics 42.2 (2008): 137-139.
[8] Alistar, Sabina S., et al. "Comparative effectiveness and cost-effectiveness of antiretro-
viral therapy and pre-exposure prophylaxis for HIV prevention in South Africa." BMC
medicine 12.1 (2014): 46.
66
Stellenbosch University  https://scholar.sun.ac.za
List of References
[9] Auvert, Bertran, et al. "Can highly active antiretroviral therapy reduce the spread
of HIV?": A study in a township of South Africa." Journal of Acquired Immune
Deficiency Syndromes 36.1 (2004): 613-621.
[10] Badri, Motasim, et al. "Cost-effectiveness of highly active antiretroviral therapy in
South Africa." PLoS Medicine 3.1 (2005): e4.
[11] Badri, Motasim, et al. "When to initiate highly active antiretroviral therapy in sub-
Saharan Africa? A South African cost-effectiveness study." Antiviral therapy 11.1
(2006): 63.
[12] Balsalobre, Pascual, et al. "Autologous stem-cell transplantation in patients with
HIV-related lymphoma." Journal of Clinical Oncology 27.13 (2009): 2192-2198.
[13] Besson, Caroline., et al. "Changes in AIDS-related lymphoma since the era of highly
active antiretroviral therapy." Blood 98.8 (2001): 2339-2344.
[14] Best, Jennie H., et al. "Cost-effectiveness analysis of rituximab combined with CHOP
for treatment of diffuse large B-cell lymphoma." Value in health 8.4 (2005): 462-470.
[15] Biggar, Robert J. "AIDS-related cancers in the era of highly active antiretroviral
therapy." Oncology 15.4 (2001): 439-48.
[16] Boshoff, Chris, et al. "AIDS-related malignancies." Nature Reviews Cancer 2.5 (2002):
373-382.
[17] Bray, Freddie, et al. "Long-term Realism and Cost-effectiveness: Primary Preven-
tion in Combatting Cancer and Associated Inequalities Worldwide." Journal of the
National Cancer Institute 107.12 (2015): 273.
[18] Bower, Mark, et al. "CD4 counts and the risk of systemic non-Hodgkin’s lymphoma
in individuals with HIV in the UK." Haematologica 94.6 (2009): 875-880.
[19] Cancer.net. "HIV and AIDS-Related Cancer: Overview". Available at: http://
www.cancer.net/cancer-types/hiv-and-aids-related-cancer/overview. (0cto-
ber 2013), online; accessed August, 2015.
[20] Cancer.net. "Types of cancer, Non-Hodgkin lymphoma stages". Available at: http://
www.cancer.net/cancer-types/lymphoma-non-hodgkin/stages. 11/2014. Accessed
August 2015.
[21] Cancer Association of South Africa (CANSA). "CANSA’s watchdog Role." Available
at: http://www.cansa.org.za/watchdog/. 2012, online: accessed May, 2015.
67
Stellenbosch University  https://scholar.sun.ac.za
List of References
[22] Cancer association of South Africa (CANSA). "Fact sheet on Non-Hodgkin lym-
phoma." Available at: http://www.cansa.org.za/files/2015/05/Fact-Sheet-
Non-Hodgkins-Lymphoma-May-2015.pdf. April 2015, pdf online; accessed September,
2015.
[23] Carbone, Antonino. "Emerging pathways in the development of AIDS-related lym-
phomas." The Lancet Oncology 4.1 (2003): 22-29.
[24] Casper, Corey. "The increasing burden of HIV-associated malignancies in resource-
limited regions." Annual Review of Medicine 62 (2011): 157-170.
[25] Castel, Amanda D., et al. "Trends in cancer diagnoses and survival among persons
with AIDS in a high HIV prevalence urban area." AIDS Care 27.7 (2015): 860-869.
[26] Centers for Disease Control and Prevention (CDC). "Effect of antiretroviral therapy
on risk of sexual transmission of HIV infection and superinfection." (2013). Accessed
May 2015.
[27] Cheson, Bruce D., et al. "Recommendations for initial evaluation, staging, and re-
sponse assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classifica-
tion." Journal of Clinical Oncology 32.27 (2014): 3059-3067.
[28] Cornell, Morna, et al. "Monitoring the South African national antiretroviral treatment
programme, 2003 - 2007: The IeDEA Southern Africa Collaboration." South African
Medical Journal 99.9 (2009): 653-660.
[29] Coutinho, Roel R. A., et al. "Highly active antiretroviral therapy and incidence of
cancer in human immunodeficiency virus-infected adults." Journal of the National
Cancer Institute 92.15 (2000): 1823-1830.
[30] Creese, Andrew, et al. "Cost-effectiveness of HIV/AIDS interventions in Africa: a
systematic review of the evidence." The Lancet 359.9318 (2002): 1635-1642.
[31] Crum-Cianflone, Nancy, et al. "Trends in the incidence of cancers among HIV-infected
persons and the impact of antiretroviral therapy: a 20-year cohort study." AIDS 23.1
(2009): 41.
[32] Danis, Marion, et al. "A prospective study of the impact of patient preferences on life-
sustaining treatment and hospital cost." Critical Care Medicine 24.11 (1996): 1811-
1817.
[33] Devleesschauwer, Brecht, et al. "DALY calculation in practice: a stepwise approach."
International Journal of Public Health 59.3 (2014): 571-574.
68
Stellenbosch University  https://scholar.sun.ac.za
List of References
[34] Devleesschauwer, Brecht, et al. "Calculating disability-adjusted life years to quantify
burden of disease." International Journal of Public Health 59.3 (2014): 565-569.
[35] De Witt, Pieter, et al. "Treatment outcomes in AIDS-related diffuse large B-cell lym-
phoma in the setting roll-out of combination antiretroviral therapy in South Africa."
Journal of Acquired Immune Deficiency Syndrome (1999) 64.1 (2013): 66-73.
[36] Diekmann, Odo, et al. "On the definition and the computation of the basic reproduc-
tion ratio R0 in models for infectious diseases in heterogeneous populations." Journal
of Mathematical Biology 28.4 (1990): 365-382.
[37] Donev, Doncho, et al. "Measuring the burden of disease: disability adjusted life year
(DALY)." Methods and Tools in Public Health 30 (2010): 715.
[38] Van den Driessche, Pauline, and James Watmough. "Reproduction numbers and
sub-threshold endemic equilibria for compartmental models of disease transmission."
Mathematical Biosciences 180.1 (2002): 29-48.
[39] Eaton, Jeffrey W., et al. "HIV treatment as prevention: systematic comparison of
mathematical models of the potential impact of antiretroviral therapy on HIV inci-
dence in South Africa." PLoS Medicine 9.7 (2012): e1001245.
[40] Eftimie, Raluca, et al. "Interactions between the immune system and cancer: a brief
review of non-spatial mathematical models." Bulletin of Mathematical Biology 73.1
(2011): 2-32.
[41] Freedberg, Kenneth A., et al. "The cost-effectiveness of preventing AIDS-related op-
portunistic infections." Jama 279.2 (1998): 130-136.
[42] Gambhir, S. S., et al. "Decision tree sensitivity analysis for cost-effectiveness of FDG-
PET in the staging and management of non-small-cell lung carcinoma." The Journal
of Nuclear Medicine 37.9 (1996): 1428.
[43] Gloghini, Annunziata, et al. "Lymphomas occurring specifically in HIV-infected pa-
tients: from pathogenesis to pathology." Seminars in Cancer Biology. Vol. 23. No. 6.
Academic Press, 2013.
[44] Gordon, Louisa G., et al. "Modelling the healthcare costs of skin cancer in South
Africa." BMC Health Services Research 16.1 (2016): 1.
[45] Goshu, Ayele Taye, and Zelalem Getahun Dessie. "Modelling progression of HIV/AIDS
disease stages using semi-Markov processes." Journal of Data Science 11.2 (2013):
269-280.
69
Stellenbosch University  https://scholar.sun.ac.za
List of References
[46] Granich, Reuben, et al. "Expanding ART for treatment and prevention of HIV in
South Africa: estimated cost and cost-effectiveness 2011-2050." PLoS One 7.2 (2012):
e30216.
[47] Guiguet, Marguerite, et al. "Effect of immunodeficiency, HIV viral load, and antiretro-
viral therapy on the risk of individual malignancies (fhdh-anrs co4): a prospective
cohort study." Lancet Oncology 10 (2009): 1152 - 1159.
[48] Haering, Matthias, et al. "Computational study to determine when to initiate and
alternate therapy in HIV infection." BioMed Research International 2014 (2014).
[49] Hawe, Penelope, et al. "What is population health intervention research?." Can J
Public Health 100.1 (2009): I8-I14.
[50] Hethcote, Herbert W. "The mathematics of infectious diseases." SIAM Review 42.4
(2000): 599-653.
[51] Holmes, Charles B., et al. "Review of human immunodeficiency virus type 1-related
opportunistic infections in sub-Saharan Africa." Clinical Infectious Diseases 36.5
(2003): 652-662.
[52] Hove-Musekwa, Senelani D., et al. "Cost-effectiveness analysis of hospitalization and
home-based care strategies for people living with HIV/AIDS: The case of Zimbabwe."
International Scholarly Research Notices 2014 (2014).
[53] Johnson, Leigh F. "Access to antiretroviral treatment in South Africa, 2004-2011."
Southern African Journal of HIV Medicine 13.1 (2012).
[54] Johnson, Leigh F., et al. "A model of the impact of HIV/AIDS and antiretrovi-
ral treatment in the Masiphumelele community." Centre for Infectious Disease Epi-
demiology and Research working paper available at http://www.cider.uct.ac.za/
publications/publications_rep. php (2011).
[55] Kahn, James G., et al. "Cost-effectiveness of male circumcision for HIV prevention in
a South African setting." PLoS Med 3.12 (2006): e517.
[56] Leukemia and Lymphoma Society. "Types of Lymphoma". Available at: https://
www.lls.org/lymphoma, online. Accessed September, 2015.
[57] Lymphoma Research Foundation. "Lymphoma fact sheets". Available at:
http://www.lymphomafacts.org/site/c.gtJSJbMUIuE/b.1190417/k.8DD6/Fact_
Sheets.htm, pdf online. Accessed September, 2015.
70
Stellenbosch University  https://scholar.sun.ac.za
List of References
[58] Manasa, Justen et al. "Primary drug resistance in South Africa: Data from 10 years
of surveys." AIDS Research and Human Retroviruses 28.6 (2012): 558-565.
[59] Mani, Deepthi, et al. "Therapy-related acute myeloid leukemia following HIV-
associated lymphoma." Clinical Lymphoma and Myeloma 9.4 (2009): 316-319.
[60] Marti-Carvajal, Arturo J., et al. "Interventions for previously untreated patients with
AIDS-associated non-Hodgkin’s lymphoma." The Cochrane Library (2009).
[61] McGrath, Nuala, et al. "Time to eligibility for antiretroviral therapy in adults with
CD4 cell count > 500 cells/µL in rural KwaZulu-Natal, South Africa." HIV Medicine
16.8 (2015): 512-518.
[62] Mocroft, Amanda, et al. "AIDS across Europe, 1994-98: the EuroSIDA study." The
Lancet 356.9226 (2000): 291-296.
[63] Muennig, Peter. "Cost-effectiveness analysis in health: a practical approach." John
Wiley & Sons, 2007.
[64] Mwamba, Peter M., et al. "AIDS-related non-Hodgkin’s lymphoma in Sub-Saharan
Africa: Current status and realities of therapeutic approach." Lymphoma 2012 (2012).
[65] Opravil, Milos, et al. "Clinical efficacy of early initiation of HAART in patients with
asymptomatic HIV infection and CD4 cell count > 350× 106/l." AIDS 16.10 (2002):
1371-1381.
[66] Palella Jr, Frank J., et al. Declining morbidity and mortality among patients with ad-
vanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
The New England Journal of Medicine. 1998;338:853-60.
[67] Palmieri, C., et al. "AIDS-related non-Hodgkin’s lymphoma in the first decade of
highly active antiretroviral therapy." QJM 99.12 (2006): 811-826.
[68] Salomon, Joshua A., et al. "Disability weights for the Global Burden of Disease 2013
study." The Lancet Global Health 3.11 (2015): 712-723.
[69] Sasco, Annie J., et al. "The challenge of AIDS-related malignancies in sub-Saharan
Africa." PLoS One 5.1 (2010): 8621.
[70] Sassi, Franco. "Calculating QALYs, comparing QALY and DALY calculations."
Health Policy and Planning 21.5 (2006): 402-408.
[71] Sengayi, Mazvita, et al. "HIV testing and burden of HIV infection in black cancer
patients in Johannesburg, South Africa: a cross-sectional study." BMC Cancer 15.1
(2015): 144.
71
Stellenbosch University  https://scholar.sun.ac.za
List of References
[72] Siegel, Joanna E., et al. "Recommendations for reporting cost-effectiveness analyses."
JAMA 276.16 (1996): 1339-1341.
[73] Simbayi, L. C., et al. "South African national HIV prevalence, incidence and behaviour
survey, 2012." Pretoria: Human Sciences Research Council (2014).
[74] Singer, Mendel E. "Cost-Effectiveness Analysis." Pharmacoeconomics 26.5 (2008):
359-361.
[75] Sitas, Freddy, et al. "The spectrum of HIV-1 related cancers in South Africa." Inter-
national Journal of Cancer 88.3 (2000): 489-492.
[76] Song, Dahye L., et al. "Cost-effectiveness analysis of brief and expanded evidence-
based risk reduction interventions for HIV-infected people who inject drugs in the
United States." PLoS One 10.2 (2015): e0116694.
[77] South African national HIV prevalence, incidence and behaviour survey, 2012. pdf
available at: "http://www.hsrc.ac.za/uploads/pageContent/4565/SABSSM%20IV%
20LEO%20final.pdf". accessed June, 2015
[78] Srivastava, Prashant Kr, et al. "Modeling the dynamics of HIV and CD4+ T cells
during primary infection." Nonlinear Analysis: Real World Applications 11.2 (2010):
612-618.
[79] Stebbing, Justin, et al. "Antiretroviral treatment regimens and immune parameters
in the prevention of systemic AIDS-related non-Hodgkin’s lymphoma." Journal of
Clinical Oncology 22.11 (2004): 2177-2183.
[80] Stein, Lara, et al. "The spectrum of human immunodeficiency virus-associated cancers
in a South African black population: Results from a case-control study, 1995-2004."
International Journal of Cancer 122.10 (2008): 2260-2265.
[81] Sterling TR, et al. "HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly
active antiretroviral therapy." AIDS 2001; 23:2251 - 2257.
[82] Ulrickson, Matthew, et al. "Epidemiology, diagnosis, and treatment of HIV-associated
non-Hodgkin lymphoma in resource-limited settings." Advances in Hematology 2012
(2012).
[83] UNAIDS press release. "Available at: http://www.unaids.org/en/resources/
presscentre/pressreleaseandstatementarchive/2013." June 2013, online ac-
cessed April, 2016.
72
Stellenbosch University  https://scholar.sun.ac.za
List of References
[84] Vishnu, Prakash, et al. "AIDS-related non-Hodgkin’s lymphoma in the era of highly
active antiretroviral therapy." Advances in Hematology 2012 (2012).
[85] Walensky, Rochelle P., et al. "Cost-effectiveness of HIV testing and treatment in the
United States." Clinical Infectious Diseases 45. Supplement 4 (2007): 248-254.
[86] Western Cape Government Hospital Tariffs. "Available at: https://www.
westerncape.gov.za/general-publication/western-cape-government-
hospital-tariffs-overview." 2016, online: accessed May, 2016.
[87] Wood, Evan, et al. "Extent to which low-level use of antiretroviral treatment could
curb the AIDS epidemic in sub-Saharan Africa." The Lancet 355.9221 (2000): 2095-
2100.
[88] Wools-Kaloustian, Kara, et al. "Viability and effectiveness of large-scale HIV treat-
ment initiatives in sub-Saharan Africa: experience from western Kenya." AIDS 20.1
(2006): 41-48.
[89] Yanik, Elizabeth L., et al. "Incidence and timing of cancer in HIV-infected individuals
following initiation of combination antiretroviral therapy." Clinical Infectious Diseases
57.5 (2013): 756-764.
73
Stellenbosch University  https://scholar.sun.ac.za
